# AMC Entertainment Holdings, Inc.: Form 10-Q for the period ended Sep 30, 2024

- Company: [AMC Entertainment Holdings, Inc.](/companies/amc.md) (CIK 1411579)
- Form: 10-Q
- Filed: 2024-11-06
- Accepted by EDGAR: Nov 6, 2024, 16:36 ET
- Period: 2024-09-30
- Accession: 0001411579-24-000077
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/1411579/000141157924000077/amc-20240930x10q.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/1411579/000141157924000077/

## Figures reported in this filing

Standardized XBRL line items for the period ended 2024-09-30.

| Line item | Period | Value | XBRL concept |
| --- | --- | ---: | --- |
| Revenue | 3 months, 2024-07-01 to 2024-09-30 | $1.35bn | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Revenue | 9 months, 2024-01-01 to 2024-09-30 | $3.33bn | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Operating income | 3 months, 2024-07-01 to 2024-09-30 | $71.8m | us-gaap:OperatingIncomeLoss |
| Operating income | 9 months, 2024-01-01 to 2024-09-30 | −$84.0m | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months, 2024-07-01 to 2024-09-30 | $119.6m | us-gaap:InterestExpenseNonoperating |
| Interest expense | 9 months, 2024-01-01 to 2024-09-30 | $319.8m | us-gaap:InterestExpenseNonoperating |
| Income tax | 3 months, 2024-07-01 to 2024-09-30 | −$1.1m | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 9 months, 2024-01-01 to 2024-09-30 | $1.4m | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months, 2024-07-01 to 2024-09-30 | −$20.7m | us-gaap:NetIncomeLoss |
| Net income | 9 months, 2024-01-01 to 2024-09-30 | −$217.0m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months, 2024-07-01 to 2024-09-30 | −$0.06 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 9 months, 2024-01-01 to 2024-09-30 | −$0.69 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months, 2024-07-01 to 2024-09-30 | −$0.06 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 9 months, 2024-01-01 to 2024-09-30 | −$0.69 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months, 2024-07-01 to 2024-09-30 | 361,853,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 9 months, 2024-01-01 to 2024-09-30 | 315,783,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 9 months, 2024-01-01 to 2024-09-30 | −$254.4m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 3 months, 2024-07-01 to 2024-09-30 | $60.7m | us-gaap:PaymentsToAcquireProductiveAssets |
| Capital expenditure | 9 months, 2024-01-01 to 2024-09-30 | $155.8m | us-gaap:PaymentsToAcquireProductiveAssets |
| Cash and equivalents | at 2024-09-30 | $527.4m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | at 2024-09-30 | $789.1m | us-gaap:AssetsCurrent |
| Total assets | at 2024-09-30 | $8.32bn | us-gaap:Assets |
| Current liabilities | at 2024-09-30 | $1.58bn | us-gaap:LiabilitiesCurrent |
| Total liabilities | at 2024-09-30 | $10.01bn | us-gaap:Liabilities |
| Long-term debt | at 2024-09-30 | $4.05bn | us-gaap:LongTermDebtNoncurrent |
| Current portion of debt | at 2024-09-30 | $95.6m | us-gaap:LongTermDebtCurrent |
| Shareholders' equity | at 2024-09-30 | −$1.69bn | us-gaap:StockholdersEquity |

## Management's discussion and analysis

As filed, 148,573 characters.

### Forward-Looking Statements

In addition to historical information, this Quarterly Report on Form 10–Q contains “forward-looking statements” within the meaning of the “safe harbor” provisions of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of words such as “may,” “will,” “forecast,” “estimate,” “project,” “intend,” “plan,” “expect,” “should,” “believe” and other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These forward-looking statements are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and trends, the economy and other future conditions and speak only as of the date on which it is made. Examples of forward-looking statements include statements we make regarding future attendance levels, revenues and our liquidity. These forward-looking statements involve known and unknown risks, uncertainties, assumptions and other factors, including those discussed in “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” which may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to, the following:

- the risks and uncertainties relating to the sufficiency of our existing cash and cash equivalents and available borrowing capacity, including following the termination of our senior secured revolving credit facility (“Senior Secured Revolving Credit Facility”), to fund operations, and satisfy obligations including cash outflows for deferred rent and planned capital expenditures currently and through the next twelve months. In order to achieve net positive cash flows provided by operating activities and long-term profitability, revenues will need to increase from current levels to levels at least in line with pre-COVID-19 revenues. However, there remain significant risks that may negatively impact revenues and attendance levels, including changes to movie studios release schedules (including as a result of production delays and delays to the release of movies caused by labor stoppages) and direct to streaming or other changing movie studio practices. If we are unable to achieve increased levels of attendance and revenues, we will be required to obtain additional liquidity. If such additional liquidity is not obtained or insufficient, we likely would seek an in-court or out-of-court restructuring of our liabilities, and in the event of such future liquidation or bankruptcy proceeding, holders of our Common Stock and other securities would likely suffer a total loss of their investment;
- the risks and uncertainties relating to the Refinancing Transactions, including, but not limited to, (i) the potential for additional future dilution of our Common Stock as a result of issuance of shares underlying our Exchangeable Notes, (ii) the possibility that the extension of certain debt maturities will not provide enough time for attendance and revenues to increase to sufficient levels and generate net positive cash flows from operating activities and long-term profitability to overcome liquidity concerns or may be

insufficient if the Company does not achieve revenue levels at least in line with pre-COVID-19 revenues and (iii) the impact on the market price of our Common Stock and our capital structure of litigation resulting from the Refinancing Transactions or any additional litigation that may arise in connection with the Refinancing Transactions. See Note 11—Commitments and Contingencies for a description of the litigation;

- changing practices of distributors, which accelerated during the COVID-19 pandemic, including increased use of alternative film delivery methods including premium video on demand, streaming platforms, shrinking exclusive theatrical release windows or release of movies to theatrical exhibition and streaming platforms on the same date, the theatrical release of fewer movies, or transitioning to other forms of entertainment;
- the impact of changing movie-going behavior of consumers;
- the risk that the North American and international box office in the near term will not recover sufficiently, resulting in higher cash burn and the need to seek additional financing;
- risks and uncertainties relating to our significant indebtedness, including our borrowings and our ability to meet our financial maintenance and other covenants;
- the dilution caused by recent and potential future sales of our Common Stock and future potential share issuances to repay, refinance, redeem or repurchase indebtedness (including expenses, accrued interest and premium, if any);
- risks relating to motion picture production, promotion, marketing, and performance, including labor stoppages affecting the production, supply and release schedule of theatrical motion picture content;
- the seasonality of our revenue and working capital, which are dependent upon the timing of motion picture releases by distributors, such releases being seasonal and resulting in higher attendance and revenues generally during the summer months and holiday seasons, and higher working capital requirements during the other periods such as the first quarter;
- intense competition in the geographic areas in which we operate among exhibitors, streaming platforms, or from other forms of entertainment;
- certain covenants in the agreements that govern our indebtedness may limit our ability to take advantage of certain business opportunities and limit or restrict our ability to pay dividends, incur additional debt, pre-pay debt, and also to refinance debt and to do so at favorable terms, and such covenants impose additional administrative and operational burdens on our business;
- risks relating to impairment losses, including with respect to goodwill and other intangibles, and theatre and other closure charges;
- general and international economic, political, regulatory, social and financial market conditions, including potential economic recession, inflation, rising interest rates, the financial stability of the banking industry, and other risks that may negatively impact discretionary income and our revenues and attendance levels;
- our lack of control over distributors of films;
- limitations on the availability of capital or poor financial results may prevent us from deploying strategic initiatives;
- an issuance of preferred stock could dilute the voting power of the common stockholders and adversely affect the market value of our outstanding Common Stock;
- limitations on the authorized number of Common Stock shares could in the future prevent us from raising additional capital through Common Stock;
- our ability to achieve expected synergies, benefits and performance from our strategic initiatives;
- our ability to refinance our indebtedness on terms favorable to us or at all;
- our ability to optimize our theatre circuit through new construction, the transformation of our existing theatres, and strategically closing underperforming theatres may be subject to delay and unanticipated costs;
- failures, unavailability or security breaches of our information systems, including due to cybersecurity incidents;
- our ability to utilize interest expense deductions will be limited annually due to Section 163(j) of the Tax Cuts and Jobs Act of 2017;
- our ability to recognize interest deduction carryforwards, net operating loss carryforwards and other tax attributes to reduce our future tax liability;
- our ability to recognize certain international deferred tax assets which currently do not have a valuation allowance recorded;
- review by antitrust authorities in connection with acquisition opportunities;
- risks relating to the incurrence of legal liability, including costs associated with the ongoing securities class action lawsuits;
- dependence on key personnel for current and future performance and our ability to attract and retain senior executives and other key personnel, including in connection with any future acquisitions;
- increased costs in order to comply or resulting from a failure to comply with governmental regulation, including the General Data Protection Regulation (“GDPR”) and all other current and pending privacy and data regulations in the jurisdictions where we have operations;
- supply chain disruptions may negatively impact our operating results;
- the availability and/or cost of energy, particularly in Europe;
- the market price and trading volume of our shares of Common Stock has been and may continue to be volatile, and purchasers of our securities could incur substantial losses;
- future offerings of debt, which would be senior to our Common Stock for purposes of distributions or upon liquidation, could adversely affect the market price of our Common Stock;
- the potential for political, social, or economic unrest, terrorism, hostilities, cyber-attacks or war, including the conflict between Russia and Ukraine and other international conflicts;
- the potential impact of financial and economic sanctions on the regional and global economy, or widespread health emergencies, such as pandemics or epidemics, causing people to avoid our theatres or other public places where large crowds are in attendance;
- anti-takeover protections in our Third Amended and Restated Certificate of Incorporation (the “Certificate of Incorporation”) and our amended and restated bylaws may discourage or prevent a takeover of our Company, even if an acquisition would be beneficial to our stockholders; and
- other risks and uncertainties referenced from time to time in filings with the SEC.

This list of factors that may affect future performance and the accuracy of forward-looking statements is illustrative but not exhaustive. In addition, new risks and uncertainties may arise from time to time. Accordingly, all forward-looking statements should be evaluated with an understanding of their inherent uncertainty and we caution accordingly against relying on forward-looking statements.

Except as required by law, we assume no obligation to publicly update or revise these forward-looking statements for any reason. Actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future.

Readers are urged to consider these factors carefully in evaluating the forward-looking statements. For further information about these and other risks and uncertainties as well as strategic initiatives, see “Item 1A. Risk Factors” of this Form 10-Q, “Item 1. Business” in our Annual Report on Form 10–K for the year ended December 31, 2023, and our other public filings.

All subsequent written and oral forward-looking statements attributable to us or persons acting on our behalf are expressly qualified in their entirety by these cautionary statements. The forward-looking statements included herein are made only as of the date of this Quarterly Report on Form 10–Q, and we do not undertake any obligation to release publicly any revisions to such forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.

### Overview

AMC is the world’s largest theatrical exhibition company and an industry leader in innovation and operational excellence. As of September 30, 2024, we operated theatres in 11 countries throughout the U.S. and Europe.

Our theatrical exhibition revenues are generated primarily from box office admissions and food and beverage sales. The balance of our revenues are generated from ancillary sources, including on-screen advertising, fees earned from our customer loyalty programs, rental of theatre auditoriums, income from gift card and exchange ticket sales, theatrical distribution, retail popcorn sales, and online ticketing fees. As of September 30, 2024, we owned, operated or had interests in 874 theatres and 9,800 screens.

### Box Office Admissions and Film Content

Box office admissions are our largest source of revenue. We predominantly license theatrical films from distributors owned by major film production companies and from independent distributors on a film-by-film and theatre-by-theatre basis. Film exhibition costs are based on a share of admissions revenues and are accrued based on estimates of the final settlement pursuant to our film licenses. These licenses typically state that rental fees are based on the box office performance of each film, though in certain circumstances and less frequently, our rental fees are based on a mutually agreed settlement rate that is fixed. In some European territories, film rental fees are established on a weekly basis and some licenses use a per capita agreement instead of a revenue share, paying a flat amount per ticket.

Our revenues attributable to individual distributors may vary significantly from year to year depending upon the commercial success of each distributor’s films in any given year. Our results of operations may vary significantly from quarter to quarter and from year to year based on the timing and popularity of film releases.

### Movie Screens

The following table provides detail with respect to large screen formats, such as IMAX® and our proprietary Dolby Cinema™, other Premium Large Format (“PLF”) screens, enhanced food and beverage offerings and our premium seating as deployed throughout our circuit:

| ​ ​ ​ Format Number of theatres: | ​ ​ ​ ​ | ​ U.S. Markets As of September 30, 2024 ​ | ​ ​ ​ | ​ 2023 ​ | ​ ​ ​ ​ ​ | ​ International Markets As of September 30, 2024 ​ | ​ ​ ​ | ​ 2023 ​ | ​ ​ ​ ​ ​ | ​ Consolidated As of September 30, 2024 ​ | ​ ​ ​ | ​ 2023 ​ |
| --- | --- | ---: | --- | ---: | --- | ---: | --- | ---: | --- | ---: | --- | ---: |
| IMAX® |  | 184 |  | 183 | ​ | 35 |  | 33 | ​ | 219 | ​ | 216 |
| Dolby Cinema™ theatres |  | 164 |  | 158 | ​ | 7 |  | 7 | ​ | 171 | ​ | 165 |
| In-house PLF |  | 60 |  | 57 | ​ | 79 |  | 75 | ​ | 139 | ​ | 132 |
| Dine-in |  | 49 |  | 49 | ​ | 3 |  | 3 | ​ | 52 | ​ | 52 |
| Premium seating | ​ | 365 | ​ | 361 | ​ | 85 | ​ | 80 | ​ | 450 | ​ | 441 |
| Offering alcohol | ​ | 384 |  | 380 | ​ | 225 |  | 231 | ​ | 609 |  | 611 |
| Number of screens: | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ |
| IMAX® | ​ | 185 | ​ | 184 | ​ | 35 | ​ | 33 | ​ | 220 | ​ | 217 |
| Dolby Cinema™ theatres | ​ | 164 | ​ | 158 | ​ | 7 | ​ | 7 | ​ | 171 | ​ | 165 |
| In-house PLF | ​ | 60 | ​ | 57 | ​ | 82 | ​ | 78 | ​ | 142 | ​ | 135 |
| Dine-in | ​ | 675 | ​ | 675 | ​ | 13 | ​ | 13 | ​ | 688 | ​ | 688 |
| Premium seating | ​ | 3,607 | ​ | 3,574 | ​ | 588 | ​ | 540 | ​ | 4,195 | ​ | 4,114 |

### Loyalty Programs and Other Marketing

As of September 30, 2024, we had approximately 34 million member households enrolled in AMC Stubs® A-List (“A-List”), AMC Stubs Premiere™ (“Premiere”) and AMC Stubs Insider™ (“Insider”) programs, combined. During the nine months ended September 30, 2024, our AMC Stubs® members represented approximately 49.0% of AMC U.S. markets attendance.

We currently have approximately 18 million members in our various International loyalty programs.

See “Item 1. Business” in our Annual Report on Form 10-K for the year ended December 31, 2023 for additional discussion and information of our screens, seating concepts, amenities, loyalty programs and other marketing initiatives.

### Holders of Shares

As of September 30, 2024, approximately 1.7 million shares of our Common Stock were directly registered with our transfer agent by 14,934 stockholders. The balance of our outstanding Common Stock was held in “street name” through bank or brokerage accounts.

### Critical Accounting Estimates

For a discussion of our critical accounting policies and the means by which we develop estimates therefore, see “Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations” in our Annual Report on Form 10-K for the year ended December 31, 2023. Material changes to our critical accounting estimates from what is described in our Form 10-K are described below:

**Derivative Liability**. We remeasure the derivative liability related to the conversion features in our Exchangeable Notes at fair value each reporting period with changes in fair value recorded in the consolidated statements of operations. We have obtained independent third-party valuation studies to assist us in determining fair value. Our valuation studies use the Binomial Lattice approach and are based on significant inputs not observable in the market and thus represent level 3 measurements within the fair value measurement hierarchy. The Binomial Lattice approach consists of simulated Common Stock prices from the valuation date to the maturity of the Exchangeable

Notes. The significant inputs used to value the derivative include the initial share price of our Common Stock, the volatility of the share price, time to maturity, risk-free interest rate, credit spread, and the discount yield. The volatility of our Common Stock, the Common Stock price at the end of each reporting period, and the remaining amount of time until maturity of the Exchangeable Notes are key inputs for the estimation of fair value that are expected to change each reporting period.

During the three and nine months ended September 30, 2024, we recorded other income related to a decline in our derivative liability fair value of $(73.5) million. We expect there will be future changes in fair value for our derivative liability and that the related amounts recorded as income or expense may be material. See Note 6—Corporate Borrowings and Finance Lease Liabilities and Note 9—Fair Value Measurements in the Notes to the Condensed Consolidated Financial Statements under Item 1 of Part I of this Form 10-Q for further information.

### Significant Events—For the Nine Months Ended September 30, 2024

**Debt Repurchases and Exchanges.** The below table summarizes the various cash debt repurchase transactions, debt for equity exchange transactions and cash and debt for equity exchange transactions that occurred during the nine months ended September 30, 2024. The debt for equity transactions were treated as early extinguishments of debt. In accordance with ASC 470-50-40-3, the reacquisition price of the extinguished debt was determined to be the fair value of the Common Stock exchanged.

*(In millions, except for share data)*

| ​ ​ ​ Cash debt repurchase transactions: | ​ ​ ​ ​ ​ | ​ ​ ​ ​ Aggregate Principal Repurchased/Exchanged ​ ​ | ​ ​ ​ ​ ​ | ​ Shares of Common Stock Exchanged ​ | ​ ​ | ​ ​ ​ ​ ​ | ​ ​ ​ ​ Reacquisition Cost ​ ​ | ​ ​ ​ ​ ​ | ​ ​ ​ ​ Gain on Extinguishment ​ ​ | ​ ​ ​ ​ ​ | ​ ​ ​ ​ Accrued Interest Paid/Exchanged ​ ​ |
| --- | --- | --- | --- | --- | ---: | --- | --- | --- | --- | --- | --- |
| 5.75% Senior Subordinated Notes due 2025 | ​ | $7.0 | ​ | ​ | — | ​ | $6.7 | ​ | $0.3 | ​ | $0.1 |
| Second Lien Notes due 2026 | ​ | ​ 50.0 | ​ | ​ | — | ​ | ​ 50.5 | ​ | ​ 4.4 | ​ | ​ 1.4 |
| Total cash debt repurchase transactions | ​ | ​ 57.0 | ​ | ​ | — | ​ | ​ 57.2 | ​ | ​ 4.7 | ​ | ​ 1.5 |
| **Debt for equity exchange transactions:** | ​ | **​** **​** | **​** | **​** | **​** | ​ | **​** **​** | **​** | **​** **​** | **​** | **​** **​** |
| Second Lien Notes due 2026 | ​ | ​ 191.4 | ​ | ​ | 27,545,325 | ​ | ​ 123.1 | ​ | ​ 91.1 | ​ | ​ 7.4 |
| Total debt for equity exchange transactions | ​ | ​ 191.4 | ​ | ​ | 27,545,325 | ​ | ​ 123.1 | ​ | ​ 91.1 | ​ | ​ 7.4 |
| **Cash and debt for equity exchange transactions:** | ​ | **​** **​** | **​** | **​** | **​** | ​ | **​** **​** | **​** | **​** **​** | **​** | **​** **​** |
| 5.75% Senior Subordinated Notes due 2025 | ​ | ​ 8.6 | ​ | ​ | 447,829 | ​ | ​ 8.4 | ​ | ​ 0.2 | ​ | ​ 0.1 |
| 5.875% Senior Subordinated Notes due 2026 | ​ | ​ 9.6 | ​ | ​ | 432,777 | ​ | ​ 8.1 | ​ | ​ 1.3 | ​ | ​ 0.2 |
| Second Lien Notes due 2026 | ​ | ​ 45.0 | ​ | ​ | 2,693,717 | ​ | ​ 45.5 | ​ | ​ 4.2 | ​ | ​ 1.2 |
| Total cash and debt for equity exchange transactions | ​ | ​ 63.2 | ​ | ​ | 3,574,323 | ​ | ​ 62.0 | ​ | ​ 5.7 | ​ | ​ 1.5 |
| Total debt repurchases and exchanges | ​ | $311.6 | ​ | ​ | 31,119,648 | ​ | $242.3 | ​ | $101.5 | ​ | $10.4 |

**Vendor Dispute.** On January 26, 2024, we executed an agreement to collect $37.5 million as resolution of a dispute with a vendor. The proceeds, net of legal costs, were recorded to other income during the nine months ended September 30, 2024. The relationship with the vendor has been restored and remains in good standing.

**Share Issuance.** During the nine months ending September 30, 2024, we raised gross proceeds of $250.0 million and paid fees to sales agents and incurred other third-party issuance costs of approximately $6.3 million and $0.6 million, respectively, through our at-the-market offering of approximately 72.5 million shares of Common Stock. We paid $0.7 million of other third-party issuance costs during the nine months ended September 30, 2024.

**Debt Refinancing.** During the three and nine months ended September 30, 2024, we completed a series of refinancing transactions with two creditor groups. See the Liquidity and Capital Resources section below for further information on these transactions.

### Significant Events—For the Nine Months Ended September 30, 2023

**Saudi Cinema Company.** On December 30, 2022, we entered into an agreement to sell our 10.0% investment in Saudi Cinema Company, LLC for SAR 112.5 million ($30.0 million), subject to certain closing conditions. On January 24, 2023, the Saudi Ministry of Commerce recorded a sale of equity and we received the proceeds on January 25, 2023. We recorded a gain on the sale of $15.5 million in investment income during the nine months ended September 30, 2023.

**Debt Repurchases.** The below table summarizes the cash debt repurchase transactions during the nine months ended September 30, 2023, including repurchases with a related party:

*(In millions)*

| ​ ​ Related party transactions: | ​ ​ ​ ​ | ​ ​ Aggregate Principal Repurchased ​ ​ | ​ ​ ​ ​ | ​ ​ Reacquisition Cost ​ ​ | ​ ​ ​ ​ | ​ ​ Gain on Extinguishment ​ ​ | ​ ​ ​ ​ | ​ ​ Accrued Interest Paid ​ ​ |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Second Lien Notes due 2026 | ​ | $75.9 | ​ | $48.5 | ​ | $40.9 | ​ | $1.1 |
| 5.875% Senior Subordinated Notes due 2026 | ​ | ​ 4.1 | ​ | ​ 1.7 | ​ | ​ 2.3 | ​ | ​ 0.1 |
| Total related party transactions | ​ | ​ 80.0 | ​ | ​ 50.2 | ​ | ​ 43.2 | ​ | ​ 1.2 |
| Non-related party transactions: | ​ | ​ ​ | ​ | ​ ​ | ​ | ​ ​ | ​ | ​ ​ |
| Second Lien Notes due 2026 | ​ | ​ 89.7 | ​ | ​ 51.3 | ​ | ​ 54.3 | ​ | ​ 2.2 |
| Total non-related party transactions | ​ | ​ 89.7 | ​ | ​ 51.3 | ​ | ​ 54.3 | ​ | ​ 2.2 |
| Total debt repurchases | ​ | $169.7 | ​ | $101.5 | ​ | $97.5 | ​ | $3.4 |

**Additional Share Issuances Antara.** On December 22, 2022, we entered into a forward purchase agreement (the “Forward Purchase Agreement”) with Antara pursuant to which we agreed to (i) sell to Antara 10,659,511 AMC Preferred Equity Units for an aggregate purchase price of $75.1 million and (ii) simultaneously purchase from Antara $100.0 million aggregate principal amount of the Company’s 10%/12% Cash/PIK Toggle Second Lien Notes in exchange for 9,102,619 AMC Preferred Equity Units. On February 7, 2023, the Company issued 19,762,130 AMC Preferred Equity Units to Antara in exchange for $75.1 million in cash and $100.0 million aggregate principal amount of the Company’s 10%/12% Cash/PIK Toggle Second Lien Notes. The Company recorded $193.7 million to stockholders’ deficit as a result of the transaction. We paid $1.4 million of accrued interest in cash upon exchange of the notes.

**Share Issuances.** During the nine months ended September 30, 2023, we entered into various equity distribution agreements with sales agents to sell shares of our Common Stock and AMC Preferred Equity Units, from time to time, through “at-the-market” offering programs.

During the nine months ended September 30, 2023, we raised gross proceeds of approximately $440.0 million and paid fees to sales agents and incurred other third-party issuance costs of approximately $11.1 million and $9.2 million, respectively, through our at-the-market offering of approximately 7.1 million shares of AMC Preferred Equity Units and 40.0 million shares of our Common Stock. We paid $11.6 million of other third-party issuance costs during the nine months ended September 30, 2023.

**Special Awards.** On February 23, 2023, the Compensation Committee approved special awards in lieu of vesting of the 2022 PSU awards. The special awards were accounted for as a modification to the 2022 Tranche Year PSU awards which lowered the Adjusted EBITDA and free cash flow performance targets such that 200% vesting was achieved for both tranches. This modification resulted in the immediate additional vesting of 238,959 Common Stock PSUs and 238,959 AMC Preferred Equity Unit PSUs. This was treated as a Type 3 modification (improbable-to-probable) which required the Company to recognize additional stock compensation expense based on the modification date fair values of the Common Stock PSUs and AMC Preferred Equity Units PSUs of $14.9 million and $5.3 million, respectively. During the nine months ended September 30, 2023, we recognized $20.2 million of additional stock compensation expense.

**Lease Termination.** During the nine months ended September 30, 2023, we received a $13.0 million buyout incentive from a landlord which provided the landlord the right to terminate the lease of one theatre. The incentive and termination gain resulted in a $16.7 million reduction to rent expense.

**NCM Bankruptcy.** On April 11, 2023, National CineMedia, LLC (“NCM”) filed a petition under Chapter 11 of the U.S. Bankruptcy Code in the Southern District of Texas. NCM is the in-theatre advertising provider for the majority of the Company’s theatres in the United States. Under the Chapter 11 plan of reorganization, which became effective on August 7, 2023 (the “Plan”), NCM has assumed its agreements with the Company. As part of the Plan, on August 7, 2023, NCM issued 16,581,829 common units (“NCM Common Units”) that were owed to the Company as part of the annual common unit adjustment. However, under the terms of the Plan and the restructuring of the equity of NCM thereunder, the NCM Common Units were immediately cancelled upon the effective date of the Plan. On August 13, 2023, in response to an appeal by the Company regarding certain terms of the Plan, including modification of the terms of the Exhibitor Services Agreement with other parties that were not similarly granted to the Company and appeal of the court’s order to approve cancellation of the NCM Common Unit issuance, the United States District Court for the

Southern District of Texas affirmed the rulings of the bankruptcy court, including confirmation of the Plan. The Company filed an appeal to these rulings with the United States Court of Appeals for the Fifth Circuit and such appeal remains pending. The Company does not expect NCM’s bankruptcy or the appeal to have a material impact on the Company.

**Shareholder Litigation.** Two putative stockholder class actions were filed in the Delaware Chancery Court, and subsequently consolidated, which asserted claims for breach of fiduciary duty against certain of our directors and a claim for breach of *8 Del. C. §* 242 against those directors and the Company, arising out of the creation of AMC Preferred Equity Units, the Antara Transactions and the Charter Amendments.

This litigation prevented us from immediately implementing the Charter Amendments. On August 11, 2023, the court approved a settlement of the Shareholder Litigation, which, among other things, permitted the implementation of the Charter Amendments. Pursuant to the terms of the settlement, record holders of Common Stock at the close of business on August 24, 2023, after giving effect to the Reverse Stock Split, but prior to the conversion of the AMC Preferred Equity Units into Common Stock, received a payment of one share of Common Stock for every 7.5 shares of Common Stock they owned. On August 28, 2023, the Company made the Settlement Payment and issued 6,897,018 shares of Common Stock. On October 13, 2023, a purported Company stockholder who objected to the settlement of the Shareholder Litigation filed a notice of appeal of the court’s decision approving the settlement. On May 22, 2024, the Delaware Supreme Court affirmed the court’s decision approving the settlement of the Shareholder Litigation.

### Operating Results

The following table sets forth our consolidated revenues, operating costs and expenses:

*(In millions)*

| ​ ​ ​ Revenues | ​ ​ ​ ​ | ​ ​ Three Months Ended September 30, 2024 ​ ​ | ​ ​ | ​ ​ 2023 ​ ​ | ​ ​ ​ | ​ ​ ​ ​ ​ % Change ​ ​ ​ | ​ ​ Nine Months Ended September 30, 2024 ​ ​ | ​ ​ | ​ ​ 2023 ​ ​ | ​ ​ ​ ​ | ​ ​ ​ ​ ​ % Change ​ ​ ​ |
| --- | --- | ---: | --- | ---: | --- | ---: | ---: | --- | ---: | --- | ---: |
| Admissions | ​ | $744.2 | ​ | $797.7 | ​ | (6.7)% | $1,839.1 | ​ | $2,075.9 | ​ | (11.4)% |
| Food and beverage | ​ | 490.4 | ​ | 482.7 | ​ | 1.6% | 1,178.7 | ​ | 1,299.6 | ​ | (9.3)% |
| Other theatre | ​ | 114.2 | ​ | 125.5 | ​ | (9.0)% | 313.0 | ​ | 332.7 | ​ | (5.9)% |
| Total revenues | ​ | ​ 1,348.8 | ​ | ​ 1,405.9 | ​ | (4.1)% | ​ 3,330.8 | ​ | ​ 3,708.2 | ​ | (10.2)% |
| **Operating Costs and Expenses** | ​ | ​ ​ | ​ | ​ ​ | ​ | ​ ​ | ​ ​ | ​ | ​ ​ | ​ | ​ ​ |
| Film exhibition costs | ​ | ​ 381.4 | ​ | ​ 398.5 | ​ | (4.3)% | ​ 893.0 | ​ | ​ 1,027.8 | ​ | (13.1)% |
| Food and beverage costs | ​ | 89.7 | ​ | 90.1 | ​ | (0.4)% | 222.6 | ​ | 243.2 | ​ | (8.5)% |
| Operating expense, excluding depreciation and amortization below | ​ | 454.6 | ​ | 449.8 | ​ | 1.1% | 1,237.9 | ​ | 1,245.0 | ​ | (0.6)% |
| Rent | ​ | 216.4 | ​ | 224.3 | ​ | (3.5)% | 659.3 | ​ | 650.8 | ​ | 1.3% |
| General and administrative: | ​ | ​ ​ | ​ | ​ ​ | ​ | ​ ​ | ​ ​ | ​ | ​ ​ | ​ | ​ ​ |
| Merger, acquisition and other costs | ​ | 0.1 | ​ | 0.7 | ​ | (85.7)% | 0.1 | ​ | 1.5 | ​ | (93.3)% |
| Other, excluding depreciation and amortization below | ​ | 54.0 | ​ | 54.4 | ​ | (0.7)% | 160.7 | ​ | 184.8 | ​ | (13.0)% |
| Depreciation and amortization | ​ | 80.8 | ​ | 88.7 | ​ | (8.9)% | 241.2 | ​ | 279.1 | ​ | (13.6)% |
| Operating costs and expenses | ​ | 1,277.0 | ​ | 1,306.5 | ​ | (2.3)% | 3,414.8 | ​ | 3,632.2 | ​ | (6.0)% |
| Operating income (loss) | ​ | 71.8 | ​ | 99.4 | ​ | (27.8)% | (84.0) | ​ | 76.0 | ​ | \*% |
| Other expense (income), net: | ​ | ​ ​ | ​ | ​ ​ | ​ | ​ ​ | ​ ​ | ​ | ​ ​ | ​ | ​ ​ |
| Other income | ​ | (22.8) | ​ | (15.9) | ​ | 43.4% | (173.8) | ​ | (10.0) | ​ | \*% |
| Interest expense: | ​ | ​ ​ | ​ | ​ ​ | ​ | ​ ​ | ​ ​ | ​ | ​ ​ | ​ | ​ ​ |
| Corporate borrowings | ​ | 109.6 | ​ | 93.4 | ​ | 17.3% | 289.8 | ​ | 276.1 | ​ | 5.0% |
| Finance lease obligations | ​ | 1.0 | ​ | 0.9 | ​ | 11.1% | 2.5 | ​ | 2.8 | ​ | (10.7)% |
| Non-cash NCM exhibitor service agreement | ​ | ​ 9.0 | ​ | ​ 9.4 | ​ | (4.3)% | ​ 27.5 | ​ | ​ 28.5 | ​ | (3.5)% |
| Investment income | ​ | (3.2) | ​ | (3.0) | ​ | 6.7% | (14.4) | ​ | (11.4) | ​ | 26.3% |
| Total other expense, net | ​ | 93.6 | ​ | 84.8 | ​ | 10.4% | 131.6 | ​ | 286.0 | ​ | (54.0)% |
| Earnings (loss) before income taxes | ​ | (21.8) | ​ | 14.6 | ​ | \*% | (215.6) | ​ | (210.0) | ​ | 2.7% |
| Income tax provision (benefit) | ​ | (1.1) | ​ | 2.3 | ​ | \*% | 1.4 | ​ | 4.6 | ​ | (69.6)% |
| Net earnings (loss) | ​ | $(20.7) | ​ | $12.3 | ​ | \*% | $(217.0) | ​ | $(214.6) | ​ | 1.1% |

\* Percentage change in excess of 100%

| ​ ​ ​ Operating Data: | ​ ​ ​ ​ | ​ Three Months Ended September 30, 2024 | ​ ​ | ​ 2023 | ​ ​ ​ | ​ Nine Months Ended September 30, 2024 | ​ ​ | ​ 2023 |
| --- | --- | ---: | --- | ---: | --- | ---: | --- | ---: |
| Screen additions |  | 13 |  | — |  | 13 |  | — |
| Screen acquisitions |  | — |  | 8 |  | 1 |  | 15 |
| Screen dispositions |  | 105 |  | 33 |  | 235 |  | 381 |
| Construction openings (closures), net |  | 3 |  | (17) |  | (38) |  | (30) |
| Average screens (1) |  | 9,534 |  | 9,781 |  | 9,618 |  | 9,885 |
| Number of screens operated | ​ | 9,800 | ​ | 10,078 | ​ | 9,800 | ​ | 10,078 |
| Number of theatres operated | ​ | 874 | ​ | 904 | ​ | 874 | ​ | 904 |
| Screens per theatre |  | 11.2 |  | 11.1 |  | 11.2 |  | 11.1 |
| Attendance (in thousands) (1) |  | 65,087 |  | 73,576 |  | 161,731 |  | 187,565 |

(1) Includes consolidated theatres only and excludes screens offline due to construction.

### Segment Operating Results

The following table sets forth our revenues, operating costs and expenses by reportable segment:

*(In millions)*

| ​ ​ ​ ​ Revenues | ​ ​ ​ ​ ​ ​ | ​ ​ U.S. Markets Three Months Ended September 30, 2024 ​ ​ | ​ ​ ​ | ​ ​ 2023 ​ ​ | ​ ​ ​ ​ ​ ​ | ​ ​ International Markets Three Months Ended September 30, 2024 ​ ​ | ​ ​ ​ | ​ ​ 2023 ​ ​ | ​ ​ ​ ​ ​ ​ | ​ ​ Consolidated Three Months Ended September 30, 2024 ​ ​ | ​ ​ ​ | ​ ​ 2023 ​ ​ |
| --- | --- | ---: | --- | ---: | --- | ---: | --- | ---: | --- | ---: | --- | ---: |
| Admissions | ​ | $572.2 | ​ | $587.5 | ​ | $172.0 | ​ | $210.2 | ​ | $744.2 | ​ | $797.7 |
| Food and beverage | ​ | 398.3 | ​ | 382.8 | ​ | 92.1 | ​ | 99.9 | ​ | 490.4 | ​ | 482.7 |
| Other theatre | ​ | 84.8 | ​ | 93.6 | ​ | 29.4 | ​ | 31.9 | ​ | 114.2 | ​ | 125.5 |
| Total revenues | ​ | ​ 1,055.3 | ​ | ​ 1,063.9 | ​ | ​ 293.5 | ​ | ​ 342.0 | ​ | ​ 1,348.8 | ​ | ​ 1,405.9 |
| **Operating Costs and Expenses** | ​ | ​ ​ | ​ | ​ ​ | ​ | ​ ​ | ​ | ​ ​ | ​ | ​ ​ | ​ | ​ ​ |
| Film exhibition costs | ​ | ​ 311.1 | ​ | ​ 309.2 | ​ | ​ 70.3 | ​ | ​ 89.3 | ​ | ​ 381.4 | ​ | ​ 398.5 |
| Food and beverage costs | ​ | 67.0 | ​ | 65.1 | ​ | 22.7 | ​ | 25.0 | ​ | 89.7 | ​ | 90.1 |
| Operating expense | ​ | 345.7 | ​ | 339.5 | ​ | 108.9 | ​ | 110.3 | ​ | 454.6 | ​ | 449.8 |
| Rent | ​ | 160.7 | ​ | 166.4 | ​ | 55.7 | ​ | 57.9 | ​ | 216.4 | ​ | 224.3 |
| General and administrative expense: | ​ | ​ ​ | ​ | ​ ​ | ​ | ​ ​ | ​ | ​ ​ | ​ | ​ ​ | ​ | ​ ​ |
| Merger, acquisition and other costs | ​ | 0.1 | ​ | 0.6 | ​ | — | ​ | 0.1 | ​ | 0.1 | ​ | 0.7 |
| Other, excluding depreciation and amortization below | ​ | 34.1 | ​ | 37.2 | ​ | 19.9 | ​ | 17.2 | ​ | 54.0 | ​ | 54.4 |
| Depreciation and amortization | ​ | 62.1 | ​ | 69.2 | ​ | 18.7 | ​ | 19.5 | ​ | 80.8 | ​ | 88.7 |
| Operating costs and expenses | ​ | 980.8 | ​ | 987.2 | ​ | 296.2 | ​ | 319.3 | ​ | 1,277.0 | ​ | 1,306.5 |
| Operating income (loss) | ​ | 74.5 | ​ | 76.7 | ​ | (2.7) | ​ | 22.7 | ​ | 71.8 | ​ | 99.4 |
| Other expense (income): | ​ | ​ ​ | ​ | ​ ​ | ​ | ​ ​ | ​ | ​ ​ | ​ | ​ ​ | ​ | ​ ​ |
| Other expense (income) | ​ | (0.2) | ​ | (27.4) | ​ | (22.6) | ​ | 11.5 | ​ | (22.8) | ​ | (15.9) |
| Interest expense: | ​ | ​ ​ | ​ | ​ ​ | ​ | ​ ​ | ​ | ​ ​ | ​ | ​ ​ | ​ | ​ ​ |
| Corporate borrowings | ​ | 94.5 | ​ | 78.7 | ​ | 15.1 | ​ | 14.7 | ​ | 109.6 | ​ | 93.4 |
| Finance lease obligations | ​ | — | ​ | 0.1 | ​ | 1.0 | ​ | 0.8 | ​ | 1.0 | ​ | 0.9 |
| Non-cash NCM exhibitor service agreement | ​ | ​ 9.0 | ​ | ​ 9.4 | ​ | ​ — | ​ | ​ — | ​ | ​ 9.0 | ​ | ​ 9.4 |
| Investment income | ​ | (3.0) | ​ | (2.4) | ​ | (0.2) | ​ | (0.6) | ​ | (3.2) | ​ | (3.0) |
| Total other expense (income), net | ​ | 100.3 | ​ | 58.4 | ​ | (6.7) | ​ | 26.4 | ​ | 93.6 | ​ | 84.8 |
| Earnings (loss) before income taxes | ​ | (25.8) | ​ | 18.3 | ​ | 4.0 | ​ | (3.7) | ​ | (21.8) | ​ | 14.6 |
| Income tax provision (benefit) | ​ | (1.9) | ​ | 0.6 | ​ | 0.8 | ​ | 1.7 | ​ | (1.1) | ​ | 2.3 |
| Net earnings (loss) | ​ | $(23.9) | ​ | $17.7 | ​ | $3.2 | ​ | $(5.4) | ​ | $(20.7) | ​ | $12.3 |

| ​ ​ ​ ​ Segment Operating Data: | ​ ​ ​ ​ ​ | ​ U.S. Markets Three Months Ended September 30, 2024 | ​ ​ | ​ 2023 | ​ ​ ​ ​ ​ | ​ International Markets Three Months Ended September 30, 2024 | ​ ​ | ​ 2023 | ​ ​ ​ ​ ​ | ​ Consolidated Three Months Ended September 30, 2024 | ​ ​ | ​ 2023 |
| --- | --- | ---: | --- | ---: | --- | ---: | --- | ---: | --- | ---: | --- | ---: |
| Screen additions |  | — |  | — | ​ | 13 | ​ | — | ​ | 13 | ​ | — |
| Screen acquisitions |  | — |  | 8 | ​ | — | ​ | — | ​ | — | ​ | 8 |
| Screen dispositions |  | 69 |  | 33 | ​ | 36 | ​ | — | ​ | 105 | ​ | 33 |
| Construction openings (closures), net |  | 2 |  | (11) | ​ | 1 | ​ | (6) | ​ | 3 | ​ | (17) |
| Average screens (1) |  | 7,179 |  | 7,356 | ​ | 2,355 | ​ | 2,425 | ​ | 9,534 | ​ | 9,781 |
| Number of screens operated | ​ | 7,195 | ​ | 7,396 | ​ | 2,605 | ​ | 2,682 | ​ | 9,800 | ​ | 10,078 |
| Number of theatres operated | ​ | 547 | ​ | 567 | ​ | 327 | ​ | 337 | ​ | 874 | ​ | 904 |
| Screens per theatre |  | 13.2 |  | 13.0 | ​ | 8.0 | ​ | 8.0 | ​ | 11.2 | ​ | 11.1 |
| Attendance (in thousands) (1) |  | 46,924 |  | 51,524 | ​ | 18,163 | ​ | 22,052 | ​ | 65,087 | ​ | 73,576 |

(1) Includes consolidated theatres only and excludes screens offline due to construction.

*(In millions)*

| ​ ​ ​ ​ Revenues | ​ ​ ​ ​ ​ ​ | ​ ​ U.S. Markets Nine Months Ended September 30, 2024 ​ ​ | ​ ​ ​ | ​ ​ 2023 ​ ​ | ​ ​ ​ ​ ​ ​ | ​ ​ International Markets Nine Months Ended September 30, 2024 ​ ​ | ​ ​ ​ | ​ ​ 2023 ​ ​ | ​ ​ ​ ​ ​ ​ | ​ ​ Consolidated Nine Months Ended September 30, 2024 ​ ​ | ​ ​ ​ | ​ ​ 2023 ​ ​ |
| --- | --- | ---: | --- | ---: | --- | ---: | --- | ---: | --- | ---: | --- | ---: |
| Admissions | ​ | $1,382.2 | ​ | $1,560.6 | ​ | $456.9 | ​ | $515.3 | ​ | $1,839.1 | ​ | $2,075.9 |
| Food and beverage | ​ | 948.8 | ​ | 1,052.4 | ​ | 229.9 | ​ | 247.2 | ​ | 1,178.7 | ​ | 1,299.6 |
| Other theatre | ​ | 229.3 | ​ | 242.8 | ​ | 83.7 | ​ | 89.9 | ​ | 313.0 | ​ | 332.7 |
| Total revenues | ​ | ​ 2,560.3 | ​ | ​ 2,855.8 | ​ | ​ 770.5 | ​ | ​ 852.4 | ​ | ​ 3,330.8 | ​ | ​ 3,708.2 |
| **Operating Costs and Expenses** | ​ | ​ ​ | ​ | ​ ​ | ​ | ​ ​ | ​ | ​ ​ | ​ | ​ ​ | ​ | ​ ​ |
| Film exhibition costs | ​ | ​ 712.8 | ​ | ​ 817.7 | ​ | ​ 180.2 | ​ | ​ 210.1 | ​ | ​ 893.0 | ​ | ​ 1,027.8 |
| Food and beverage costs | ​ | 165.8 | ​ | 181.2 | ​ | 56.8 | ​ | 62.0 | ​ | 222.6 | ​ | 243.2 |
| Operating expense | ​ | 926.0 | ​ | 930.4 | ​ | 311.9 | ​ | 314.6 | ​ | 1,237.9 | ​ | 1,245.0 |
| Rent | ​ | 489.0 | ​ | 485.0 | ​ | 170.3 | ​ | 165.8 | ​ | 659.3 | ​ | 650.8 |
| General and administrative expense: | ​ | ​ ​ | ​ | ​ ​ | ​ | ​ ​ | ​ | ​ ​ | ​ | ​ ​ | ​ | ​ ​ |
| Merger, acquisition and other costs | ​ | 0.1 | ​ | 1.4 | ​ | — | ​ | 0.1 | ​ | 0.1 | ​ | 1.5 |
| Other | ​ | 105.1 | ​ | 130.9 | ​ | 55.6 | ​ | 53.9 | ​ | 160.7 | ​ | 184.8 |
| Depreciation and amortization | ​ | 187.0 | ​ | 218.7 | ​ | 54.2 | ​ | 60.4 | ​ | 241.2 | ​ | 279.1 |
| Operating costs and expenses | ​ | 2,585.8 | ​ | 2,765.3 | ​ | 829.0 | ​ | 866.9 | ​ | 3,414.8 | ​ | 3,632.2 |
| Operating income (loss) | ​ | (25.5) | ​ | 90.5 | ​ | (58.5) | ​ | (14.5) | ​ | (84.0) | ​ | 76.0 |
| Other expense (income): | ​ | ​ ​ | ​ | ​ ​ | ​ | ​ ​ | ​ | ​ ​ | ​ | ​ ​ | ​ | ​ ​ |
| Other income | ​ | (117.9) | ​ | (5.6) | ​ | (55.9) | ​ | (4.4) | ​ | (173.8) | ​ | (10.0) |
| Interest expense: | ​ | ​ ​ | ​ | ​ ​ | ​ | ​ ​ | ​ | ​ ​ | ​ | ​ ​ | ​ | ​ ​ |
| Corporate borrowings | ​ | 244.9 | ​ | 232.1 | ​ | 44.9 | ​ | 44.0 | ​ | 289.8 | ​ | 276.1 |
| Finance lease obligations | ​ | 0.1 | ​ | 0.2 | ​ | 2.4 | ​ | 2.6 | ​ | 2.5 | ​ | 2.8 |
| Non-cash NCM exhibitor service agreement | ​ | ​ 27.5 | ​ | ​ 28.5 | ​ | ​ — | ​ | ​ — | ​ | ​ 27.5 | ​ | ​ 28.5 |
| Investment expense (income) | ​ | (13.0) | ​ | 4.7 | ​ | (1.4) | ​ | (16.1) | ​ | (14.4) | ​ | (11.4) |
| Total other expense (income), net | ​ | 141.6 | ​ | 259.9 | ​ | (10.0) | ​ | 26.1 | ​ | 131.6 | ​ | 286.0 |
| Loss before income taxes | ​ | (167.1) | ​ | (169.4) | ​ | (48.5) | ​ | (40.6) | ​ | (215.6) | ​ | (210.0) |
| Income tax provision (benefit) | ​ | (0.7) | ​ | 1.6 | ​ | 2.1 | ​ | 3.0 | ​ | 1.4 | ​ | 4.6 |
| Net loss | ​ | $(166.4) | ​ | $(171.0) | ​ | $(50.6) | ​ | $(43.6) | ​ | $(217.0) | ​ | $(214.6) |

| ​ ​ ​ ​ Segment Operating Data: | ​ ​ ​ ​ ​ | ​ U.S. Markets Nine Months Ended September 30, 2024 | ​ ​ | ​ 2023 | ​ ​ ​ ​ ​ | ​ International Markets Nine Months Ended September 30, 2024 | ​ ​ | ​ 2023 | ​ ​ ​ ​ ​ | ​ Consolidated Nine Months Ended September 30, 2024 | ​ ​ | ​ 2023 |
| --- | --- | ---: | --- | ---: | --- | ---: | --- | ---: | --- | ---: | --- | ---: |
| Screen additions | ​ | — |  | — | ​ | 13 | ​ | — | ​ | 13 | ​ | — |
| Screen acquisitions |  | — |  | 8 | ​ | 1 | ​ | 7 | ​ | 1 | ​ | 15 |
| Screen dispositions |  | 157 |  | 244 | ​ | 78 | ​ | 137 | ​ | 235 | ​ | 381 |
| Construction openings (closures), net |  | (17) |  | (16) | ​ | (21) | ​ | (14) | ​ | (38) | ​ | (30) |
| Average screens (1) |  | 7,231 |  | 7,429 | ​ | 2,387 | ​ | 2,456 | ​ | 9,618 | ​ | 9,885 |
| Number of screens operated | ​ | 7,195 | ​ | 7,396 | ​ | 2,605 | ​ | 2,682 | ​ | 9,800 | ​ | 10,078 |
| Number of theatres operated |  | 547 |  | 567 | ​ | 327 | ​ | 337 | ​ | 874 | ​ | 904 |
| Screens per theatre |  | 13.2 |  | 13.0 | ​ | 8.0 | ​ | 8.0 | ​ | 11.2 | ​ | 11.1 |
| Attendance (in thousands) (1) |  | 113,907 |  | 133,909 | ​ | 47,824 | ​ | 53,656 | ​ | 161,731 | ​ | 187,565 |

(1) Includes consolidated theatres only and excludes screens offline due to construction.

### Segment Information

Our historical results of operations for the three and nine months ended September 30, 2024 and September 30, 2023, reflect the results of operations for our two theatrical exhibition reportable segments, U.S. markets and International markets.

### Results of Operations—For the Three Months ended September 30, 2024, Compared to the Three Months ended September 30, 2023

### Condensed Consolidated Results of Operations

**Revenues.** Total revenues decreased $57.1 million, or 4.1%, during the three months ended September 30, 2024, compared to the three months ended September 30, 2023. Admissions revenues decreased $53.5 million, or 6.7%, during the three months ended September 30, 2024, compared to the three months ended September 30, 2023, primarily due to a decrease in attendance of 11.5% from 73.6 million patrons to 65.1 million patrons, partially offset by a 5.4% increase in average ticket price. In our U.S. markets our market share of box office revenues declined for the three months ended September 30, 2024, compared to the three months ended September 30, 2023 driven by the interplay between the film slate and our geographic mix. In our International markets attendance declined due to the popularity of film product compared to the prior year. The increase in average ticket price was primarily due to increased ticket prices for all formats, increases in 3D, other PLF and IMAX screen volumes as a percentage of attendance and increases in attendance for alternative content.

Food and beverage revenues increased $7.7 million, or 1.6%, during the three months ended September 30, 2024, compared to the three months ended September 30, 2023, primarily due to the increase in food and beverage per patron, partially offset by the decrease in attendance. Food and beverage per patron increased 14.8% from $6.56 to $7.53 due primarily to an increase in average prices and the percentage of guests making transactions, partially offset by lower units purchase per transaction and more frequent attendance from our AMC Stubs members.

Total other theatre revenues decreased $11.3 million, or 9.0%, during the three months ended September 30, 2024, compared to the three months ended September 30, 2023, primarily due to the decline in attendance and a decline in the number of tickets purchased online subject to convenience fees, which resulted in lower ticket fee and advertising revenues.

**Operating costs and expenses.** Operating costs and expenses decreased $29.5 million, or 2.3%, during the three months ended September 30, 2024, compared to the three months ended September 30, 2023. Film exhibition costs decreased $17.1 million, or 4.3%, during the three months ended September 30, 2024, compared to the three months ended September 30, 2023, primarily due to the decrease in admissions revenues, partially offset by higher film rental terms. As a percentage of admissions revenues, film exhibition costs were 51.2% for the three months ended September 30, 2024, compared to 50.0% for the three months ended September 30, 2023. The increase in film exhibition cost percentage is primarily due to higher film rental terms in U.S. markets on top grossing films and alternative content during the three months ended September 30, 2024, compared to the three months ended September 30, 2023.

Food and beverage costs decreased $0.4 million, or 0.4%, during the three months ended September 30, 2024, compared to the three months ended September 30, 2023. The decrease in food and beverage costs was primarily due to lower costs, partially offset by the increase in food and beverage revenues. As a percentage of food and beverage revenues, food and beverage costs were 18.3% for the three months ended September 30, 2024, compared to 18.7% for the three months ended September 30, 2023.

Operating expense increased by $4.8 million, or 1.1%, during the three months ended September 30, 2024, compared to the three months ended September 30, 2023. The increase in operating expense was primarily due to increases in equipment expense, premium format expense, and insurance, partially offset by decreases in utilities and advertising. As a percentage of revenues, operating expense was 33.7% for the three months ended September 30, 2024, compared to 32.0% for the three months ended September 30, 2023. Rent expense decreased 3.5%, or $7.9 million, during the three months ended September 30, 2024, compared to the three months ended September 30, 2023.

**Merger, acquisition, and other costs.** Merger, acquisition, and other costs were $0.1 million during the three months ended September 30, 2024, compared to $0.7 million during the three months ended September 30, 2023.

**Other.** Other general and administrative expense decreased $0.4 million, or 0.7%, during the three months ended September 30, 2024, compared to the three months ended September 30, 2023, due primarily to declines in bonus expense as a result of lower-than-expected annual performance compared to annual targets in the current year compared to the prior year and lower stock-based compensation expense. See Note 7—Stockholders’ Deficit in the Notes to the Condensed Consolidated Financial Statements under Item 1 of Part I of this Form 10-Q for additional information about stock-based compensation expense.

**Depreciation and amortization.** Depreciation and amortization decreased $7.9 million, or 8.9%, during the three months ended September 30, 2024, compared to the three months ended September 30, 2023, primarily due to theatre closures and lower depreciation expense on theatres impaired during the year ended December 31, 2023.

**Other income.** Other income of $22.8 million during the three months ended September 30, 2024 was primarily due to $73.5 million of income related to the decrease in fair value of the Conversion Option derivative liability, $21.5 million in foreign currency transaction gains, $14.9 million of recoveries related to the Shareholder Litigation, $5.2 million in equity in earnings related to non-consolidated entities, gain on extinguishment of debt of $1.3 million related to the redemption of $9.57 million aggregate principal amount of the Senior Subordinated Notes due 2026, and gain on extinguishment of debt of $0.5 million related to the redemption of $15.6 million aggregate principal amount of Senior Subordinated Notes due 2025, partially offset by a loss on extinguishment of debt of $52.6 million related to the redemption of $613.65 million aggregate principal amount of the Second Lien Notes and $41.0 million of third party costs related to the modification of the Existing Term Loans. Other income of $15.9 million during the three months ended September 30, 2023 was primarily due to $15.3 million of income related to the settlement of the Shareholder Litigation comprised of $16.1 million of non-cash income for the decrease in estimated fair value as of the date of the final Delaware Supreme Court order of settlement shares issued to holders of Common Stock on August 28, 2023, partially offset by $0.8 million of contingent insurance recovery costs, gains on extinguishment of debt of $10.8 million related to the redemption of $24.2 million aggregate principal amount of the Second Lien Notes, and equity earnings from non-consolidated entities of $3.1 million, partially offset by $12.8 million in foreign currency transaction losses. See Note 1—Basis of Presentation in the Notes to the Condensed Consolidated Financial Statements under Item 1 of Part I of this Form 10-Q for additional information about the components of other expense (income).

**Interest expense.** Interest expense increased $15.9 million to $119.6 million for the three months ended September 30, 2024, compared to $103.7 million during the three months ended September 30, 2023, primarily due to increased interest expense of $18.0 million on the New Term Loans compared to the Existing Term Loans, and interest expense of $7.9 million on the Exchangeable Notes issued on July 22, 2024, partially offset by declines in interest expense of $9.0 million on the Second Lien Notes due to redemptions of principal balances and declines in interest expense related to the revolving credit facility of $1.0 million. See Note 6—Corporate Borrowings and Finance Lease Liabilities in the Notes to the Condensed Consolidated Financial Statements under Item 1 of Part I of this Form 10-Q for additional information about our indebtedness.

**Investment income.** Investment income was $3.2 million for the three months ended September 30, 2024, compared to income of $3.0 million for the three months ended September 30, 2023. Investment income in the current year includes interest income of $4.6 million and $0.3 million of increase in estimated fair value of our investment in common shares of Hycroft, partially offset by $1.7 million of decrease in estimated fair value of our investment in warrants to purchase common shares of Hycroft. Investment income in the prior year includes $3.7 million of interest income and $0.1 million of increase in our investment in common shares of Hycroft, partially offset by decline in estimated fair value of $0.8 million in our investment in warrants to purchase common shares of Hycroft.

**Income tax provision (benefit).** The income tax benefit was $(1.1) million, compared to a provision of $2.3 million, for the three months ended September 30, 2024, and September 30, 2023, respectively. See Note 8—Income Taxes in the Notes to the Condensed Consolidated Financial Statements under Item 1 of Part I of this Form 10-Q for further information.

**Net earnings (loss).** Net earnings (loss) was $(20.7) million and $12.3 million during the three months ended September 30, 2024, and September 30, 2023, respectively. Net loss during the three months ended September 30, 2024 compared to net earnings for the three months ended September 30, 2023 was negatively impacted by the decrease in attendance as a result of the decline in market share in U.S. markets and the popularity of new film releases in International markets compared to the prior year and an increase in interest expense, partially offset by decreases in rent expense, general and administrative expense, depreciation and amortization, increases in investment income, increases in other income and decreases in income tax provision.

### Theatrical Exhibition—U.S. Markets

**Revenues.** Total revenues decreased $8.6 million, or 0.8%, during the three months ended September 30, 2024, compared to the three months ended September 30, 2023. Admissions revenues decreased $15.3 million, or 2.6%, during the three months ended September 30, 2024, compared to the three months ended September 30, 2023, primarily due to a decrease in attendance of 8.9% from 51.5 million patrons to 46.9 million patrons, partially offset by a 6.9% increase in average ticket price. Our market share of box office revenues declined for the three months ended September 30, 2024, compared to the three months ended September 30, 2023 driven by the interplay between the film slate and our geographic mix. The increase in average ticket price was primarily due to increased ticket prices for all formats, increases in 3D, other PLF and IMAX screen volumes as a percentage of attendance and increases in attendance for alternative content.

Food and beverage revenues increased $15.5 million, or 4.0%, during the three months ended September 30, 2024, compared to the three months ended September 30, 2023, primarily due to the increase in food and beverage per patron, partially offset by the decrease in attendance. Food and beverage per patron increased 14.3% from $7.43 to $8.49 due primarily to an increase in average prices and the percentage of guests making transactions, partially offset by lower units purchase per transaction and more frequent attendance from our AMC Stubs members.

Total other theatre revenues decreased $8.8 million, or 9.4%, during the three months ended September 30, 2024, compared to the three months ended September 30, 2023, primarily due to decline in attendance and a decline in the number of tickets purchased online subject to convenience fees, which resulted in lower ticket fee and advertising revenues.

**Operating costs and expenses.** Operating costs and expenses decreased $6.4 million, or 0.6%, during the three months ended September 30, 2024, compared to the three months ended September 30, 2023. Film exhibition costs increased $1.9 million, or 0.6%, during the three months ended September 30, 2024, compared to the three months ended September 30, 2023, primarily due to the decrease in admissions revenues, partially offset by higher film rental terms. As a percentage of admissions revenues, film exhibition costs were 54.4% for the three months ended September 30, 2024, compared to 52.6% for the three months ended September 30, 2023. The increase in film exhibition cost percentage is primarily due to higher film rental terms on top grossing films and alternative content during the three months ended September 30, 2024 compared to the three months ended September 30, 2023.

Food and beverage costs increased $1.9 million, or 2.9%, during the three months ended September 30, 2024, compared to the three months ended September 30, 2023. The increase in food and beverage costs was primarily due to the increase in food and beverage revenues, partially offset by lower costs. As a percentage of food and beverage revenues, food and beverage costs were 16.8% for the three months ended September 30, 2024, compared to 17.0% for the three months ended September 30, 2023.

Operating expense increased by $6.2 million, or 1.8%, during the three months ended September 30, 2024, compared to the three months ended September 30, 2023. The increase in operating expense was primarily due to increases in equipment expense, premium format expense, and insurance, partially offset by decreases in utilities and advertising. As a percentage of revenues, operating expense was 32.8% for the three months ended September 30, 2024, compared to 31.9% for the three months ended September 30, 2023. Rent expense decreased 3.4%, or $5.7 million, during the three months ended September 30, 2024, compared to the three months ended September 30, 2023.

**Merger, acquisition, and other costs.** Merger, acquisition, and other costs were $0.1 million during the three months ended September 30, 2024, compared to $0.6 million during the three months ended September 30, 2023.

**Other.** Other general and administrative expense decreased $3.1 million, or 8.3%, during the three months ended September 30, 2024, compared to the three months ended September 30, 2023, due primarily to declines in bonus expense as a result of lower-than-expected annual performance compared to annual targets in the current year compared to the prior year and lower stock-based compensation expense. See Note 7—Stockholders’ Deficit in the Notes to the Condensed Consolidated Financial Statements under Item 1 of Part I of this Form 10-Q for additional information about stock-based compensation expense.

**Depreciation and amortization.** Depreciation and amortization decreased $7.1 million, or 10.3%, during the three months ended September 30, 2024, compared to the three months ended September 30, 2023, primarily due to theatre closures and lower depreciation expense on theatres impaired during the year ended December 31, 2023.

**Other income.** Other income of $0.2 million during the three months ended September 30, 2024 was primarily due to $73.5 million of income related to the decrease in fair value of the Conversion Option derivative liability, $14.9 million of recoveries related to the Shareholder Litigation, $4.5 million in equity in earnings related to non-consolidated entities, gain on extinguishment of debt of $1.3 million related to the redemption of $9.57 million aggregate principal amount of the Senior Subordinated Notes due 2026, and gain on extinguishment of debt of $0.5 million related to the redemption of $15.6 million aggregate principal amount of Senior Subordinated Notes due 2025, partially offset by a loss on extinguishment of debt of $52.6 million related to the redemption of $613.65 million aggregate principal amount of the Second Lien Notes and $41.0 million of third party costs related to the modification of the Existing Term Loans. Other income of $27.4 million during the three months ended September 30, 2023 was primarily due to $15.3 million of income related to the settlement of the Shareholder Litigation comprised of $16.1 million of non-cash income for the decrease in estimated fair value as of the date of the final Delaware Supreme Court order of settlement shares issued to holders of Common Stock on August 28, 2023, partially offset by $0.8 million of contingent insurance recovery costs, gains on extinguishment of debt of $10.8 million related to the redemption of $24.2 million aggregate principal amount of the Second Lien Notes and equity earnings from non-consolidated entities of $1.5 million. See Note 1—Basis of Presentation in the Notes to the Condensed Consolidated Financial Statements under Item 1 of Part I of this Form 10-Q for additional information about the components of other expense (income).

**Interest expense.** Interest expense increased $15.3 million to $103.5 million for the three months ended September 30, 2024, compared to $88.2 million during the three months ended September 30, 2023, primarily due to increased interest expense of $18.0 million on the New Term Loans compared to the Existing Term Loans, and interest expense of $7.9 million on the Exchangeable Notes issued on July 22, 2024, partially offset by declines in interest expense of $9.0 million on the Second Lien Notes due to redemptions of principal balances and declines in interest expense related to the revolving credit facility of $1.0 million. See Note 6—Corporate Borrowings and Finance Lease Liabilities in the Notes to the Condensed Consolidated Financial Statements under Item 1 of Part I of this Form 10-Q for additional information about our indebtedness.

**Investment income.** Investment income was $3.0 million for the three months ended September 30, 2024, compared to income of $2.4 million for the three months ended September 30, 2023. Investment income in the current year includes interest income of $4.4 million and $0.3 million of increase in estimated fair value of our investment in common shares of Hycroft, partially offset by $1.7 million of decrease in estimated fair value of our investment in warrants to purchase common shares of Hycroft. Investment income in the prior year includes $(3.1) million in interest income and $(0.1) million of increase in estimated fair value of our investment in common shares of Hycroft, partially offset by $0.8 million of decline in estimated fair value of our investment in warrants to purchase common shares of Hycroft.

**Income tax provision (benefit).** The income tax benefit was $(1.9) million, compared to a provision of $0.6 million, for the three months ended September 30, 2024, and September 30, 2023, respectively. See Note 8—Income Taxes in the Notes to the Condensed Consolidated Financial Statements under Item 1 of Part I of this Form 10-Q for further information.

**Net earnings (loss).** Net earnings (loss) was $(23.9) million and $17.7 million during the three months ended September 30, 2024, and September 30, 2023, respectively. Net loss during the three months ended September 30, 2024 compared to net earnings for the three months ended September 30, 2023 was negatively impacted by the decrease in attendance as a result of the decline in market share compared to the prior year and decreases in other income and an increase in interest expense, partially offset by decreases in rent expense, general and administrative expense, depreciation and amortization, increases in investment income and decreases in income tax provision.

### Theatrical Exhibition—International Markets

**Revenues.** Total revenues decreased $48.5 million, or 14.2%, during the three months ended September 30, 2024, compared to the three months ended September 30, 2023. Admissions revenues decreased $38.2 million, or 18.2%, during the three months ended September 30, 2024, compared to the three months ended September 30, 2023, primarily due to a decrease in attendance of 17.6% from 22.1 million patrons to 18.2 million patrons and a decrease in average ticket price of 0.6%. The decrease in attendance was primarily due to the popularity of film product compared to the prior year.

Food and beverage revenues decreased $7.8 million, or 7.8%, during the three months ended September 30, 2024, compared to the three months ended September 30, 2023, primarily due to the decrease in attendance, partially offset by an increase in food and beverage per patron. Food and beverage per patron increased 11.9% from $4.53 to $5.07 primarily due to an increase in average prices and the percentage of guests making transactions.

Total other theatre revenues decreased $2.5 million, or 7.8%, during the three months ended September 30, 2024, compared to the three months ended September 30, 2023, primarily due to the decline in attendance and a decline in the number of tickets purchased online subject to convenience fees, which resulted in lower ticket fee and advertising revenues.

**Operating costs and expenses.** Operating costs and expenses decreased $23.1 million, or 7.2%, during the three months ended September 30, 2024, compared to the three months ended September 30, 2023. Film exhibition costs decreased $19.0 million, or 21.3%, during the three months ended September 30, 2024, compared to the three months ended September 30, 2023, primarily due to the decrease in attendance and lower film rental terms. As a percentage of admissions revenues, film exhibition costs were 40.9% for the three months ended September 30, 2024, compared to 42.5% for the three months ended September 30, 2023. The decrease in film exhibition cost percentage is primarily due to the concentration of box office revenues in higher grossing films in the prior year, which typically results in higher film exhibition costs.

Food and beverage costs decreased $2.3 million, or 9.2%, during the three months ended September 30, 2024, compared to the three months ended September 30, 2023. The decrease in food and beverage costs was primarily due to the decrease in food and beverage revenues. As a percentage of food and beverage revenues, food and beverage costs were 24.6% for the three months ended September 30, 2024, compared to 25.0% for the three months ended September 30, 2023.

Operating expense decreased by $1.4 million, or 1.3%, during the three months ended September 30, 2024, compared to the three months ended September 30, 2023. The decrease in operating expense was primarily due to lower utilities expense and the decrease in attendance. As a percentage of revenues, operating expense was 37.1% for the three months ended September 30, 2024, compared to 32.3% for the three months ended September 30, 2023. Rent expense decreased 3.8%, or $2.2 million, during the three months ended September 30, 2024, compared to the three months ended September 30, 2023.

**Other.** Other general and administrative expense increased $2.7 million, or 15.7%, during the three months ended September 30, 2024, compared to the three months ended September 30, 2023, primarily due to payroll and related costs.

**Depreciation and amortization.** Depreciation and amortization decreased $0.8 million, or 4.1%, during the three months ended September 30, 2024, compared to the three months ended September 30, 2023, primarily due to theatre closures and lower depreciation expense on theatres impaired during the year ended December 31, 2023.

**Other expense (income).** Other expense (income) of $(22.6) million during the three months ended September 30, 2024 was primarily due to foreign currency transaction gains of $(21.9) million and equity in earnings of non-consolidated entities of $(0.7) million. Other expense of $11.5 million during the three months ended September 30, 2023 was primarily due to $12.8 million in foreign currency transaction losses, partially offset by equity in earnings of non-consolidated entities of $(1.6) million. See Note 1—Basis of Presentation in the Notes to the Condensed Consolidated Financial Statements under Item 1 of Part I of this Form 10-Q for additional information about the components of other expense (income).

**Interest expense.** Interest expense increased $0.6 million to $16.1 million for the three months ended September 30, 2024, compared to $15.5 million for the three months ended September 30, 2023. See Note 6—Corporate Borrowings and Finance Lease Liabilities in the Notes to the Condensed Consolidated Financial Statements under Item 1 of Part I of this Form 10-Q for additional information about our indebtedness.

**Investment income.** Investment income was $0.2 million for the three months ended September 30, 2024, compared to income of $0.6 million for the three months ended September 30, 2023. Investment income in the current and prior year is comprised of interest income.

**Income tax provision.** The income tax provision was $0.8 million and $1.7 million for the three months ended September 30, 2024, and September 30, 2023, respectively. See Note 8—Income Taxes in the Notes to the Condensed Consolidated Financial Statements under Item 1 of Part I of this Form 10-Q for further information.

**Net earnings (loss).** Net earnings (loss) was $3.2 million and $(5.4) million during the three months ended September 30, 2024, and September 30, 2023, respectively. Net earnings during the three months ended September 30, 2024 compared to net loss for the three months ended September 30, 2023 was positively impacted by decreases in depreciation and amortization expense, and decreases in rent expense and decreases in other expense, partially offset by the decrease in attendance as a result of the popularity of new film releases compared to the prior year, increases in general and administrative expense, increases in interest expense and decreases in income tax benefit.

### Results of Operations—For the Nine Months ended September 30, 2024 Compared to the Nine Months ended September 30, 2023

### Condensed Consolidated Results of Operations

**Revenues.** Total revenues decreased $377.4 million, or 10.2%, during the nine months ended September 30, 2024, compared to the nine months ended September 30, 2023. Admissions revenues decreased $236.8 million, or 11.4%, during the nine months ended September 30, 2024, compared to the nine months ended September 30, 2023, primarily due to a decrease in attendance of 13.8% from 187.6 million patrons to 161.7 million patrons, partially offset by a 2.7% increase in average ticket price. The decrease in attendance was primarily due to the popularity of film product in U.S. markets compared to the prior year. The availability and popularity of film product released during the nine months ended September 30, 2024, was negatively impacted by labor stoppages during 2023. The increase in average ticket price was primarily due to increased ticket prices for all formats, increases in IMAX and other PLF screen volumes as a percentage of attendance and increases in attendance for alternative content.

Food and beverage revenues decreased $120.9 million, or 9.3%, during the nine months ended September 30, 2024, compared to the nine months ended September 30, 2023, primarily due to the decrease in attendance, partially offset by an increase in food and beverage per patron. Food and beverage per patron increased 5.2% from $6.93 to $7.29 due primarily to an increase in average prices, partially offset by lower units purchase per transaction, a decline in the percentage of guests making transactions and more frequent attendance from our AMC Stubs members.

Total other theatre revenues decreased $19.7 million, or 5.9%, during the nine months ended September 30, 2024, compared to the nine months ended September 30, 2023, primarily due to the decline in attendance which resulted in lower ticket fees and advertising revenues.

**Operating costs and expenses.** Operating costs and expenses decreased $217.4 million, or 6.0%, during the nine months ended September 30, 2024, compared to the nine months ended September 30, 2023. Film exhibition costs decreased $134.8 million, or 13.1%, during the nine months ended September 30, 2024, compared to the nine months ended September 30, 2023, primarily due to the decrease in attendance and lower film rental terms. As a percentage of admissions revenues, film exhibition costs were 48.6% for the nine months ended September 30, 2024, compared to 49.5% for the nine months ended September 30, 2023. The decrease in film exhibition cost percentage is primarily due to the concentration of box office revenues in higher grossing films in the prior year, which typically results in higher film exhibition costs.

Food and beverage costs decreased $20.6 million, or 8.5%, during the nine months ended September 30, 2024, compared to the nine months ended September 30, 2023. The decrease in food and beverage costs was primarily due to lower food and beverage revenues. As a percentage of food and beverage revenues, food and beverage costs were 18.9% for the nine months ended September 30, 2024, compared to 18.7% for the nine months ended September 30, 2023.

Operating expense decreased by $7.1 million, or 0.6%, during the nine months ended September 30, 2024, compared to the nine months ended September 30, 2023. The decrease in operating expense was primarily due to the decrease in attendance. As a percentage of revenues, operating expense was 37.2% for the nine months ended September 30, 2024, compared to 33.6% for the nine months ended September 30, 2023. Rent expense increased 1.3%, or $8.5 million, during the nine months ended September 30, 2024, compared to the nine months ended September 30, 2023, primarily due to the early termination of one theatre lease for a benefit of $16.7 million in the prior year, which included an early termination payment from the landlord for $13.0 million.

**Merger, acquisition, and other costs.** Merger, acquisition, and other costs were $0.1 million during the nine months ended September 30, 2024, compared to $1.5 million during the nine months ended September 30, 2023.

**Other.** Other general and administrative expense decreased $24.1 million, or 13.0%, during the nine months ended September 30, 2024, compared to the nine months ended September 30, 2023, due primarily to lower stock-based compensation expense and declines in bonus expense, as a result of lower expected annual performance compared to annual targets in the current year compared to the prior year. We recorded $2.1 million of stock-based compensation expense during the nine months ended September 30, 2024 compared to $20.2 million during the nine months ended September 30, 2023 related to special awards in each year accounted for as a modification to the respective 2023 and 2022 PSU awards which lowered the Adjusted EBITDA and free cash flow performance targets such that 200% vesting was achieved for both tranches in 2023 and 2022. See Note 7—Stockholders’ Deficit in the Notes to the Condensed Consolidated Financial Statements under Item 1 of Part I of this Form 10-Q for additional information about stock-based compensation expense.

**Depreciation and amortization.** Depreciation and amortization decreased $37.9 million, or 13.6%, during the nine months ended September 30, 2024, compared to the nine months ended September 30, 2023, primarily due to theatre closures and lower depreciation expense on theatres impaired during the year ended December 31, 2023.

**Other income.** Other income of $173.8 million during the nine months ended September 30, 2024 was primarily due to $73.5 million of income related to the decrease in fair value of the Conversion Option derivative liability, a gain on extinguishment of debt of $38.5 million related to the redemption of $805.0 million aggregate principal amount of the Second Lien Notes, the favorable settlement of a vendor dispute of $36.2 million, $34.0 million of recoveries related to the Shareholder Litigation, $18.9 million of foreign currency transaction gains, $9.9 million of equity in earnings of non-consolidated entities and $3.6 million of other settlement proceeds, partially offset by $41.0 million of third party costs related to the modification of the Existing Term Loans. Other income of $10.0 million during the nine months ended September 30, 2023 was primarily due to a gain on extinguishment of debt of $95.2 million related to the redemption of $165.6 million aggregate principal amount of the Second Lien Notes, a gain on extinguishment of debt of $2.3 million related to the redemption of $4.1 million aggregate principal amount of our Senior Subordinated Notes due 2026, a receipt of $14.0 million in settlement of the Lao Action, equity in earnings of non-consolidated entities of $5.3 million and $3.2 million in foreign currency transaction gains, partially offset by, $110.1 million of expense related to the settlement of the Shareholder Litigation comprised of $10.8 million of estimated legal fees and contingent insurance recovery costs and $99.3 million of non-cash expense for the estimated fair value as of the date of the final Delaware Supreme Court order of settlement shares issued to holders of Common Stock on August 28, 2023. See Note 1—Basis of Presentation in the Notes to the Condensed Consolidated Financial Statements under Item 1 of Part I of this Form 10-Q for additional information about the components of other expense (income).

**Interest expense.** Interest expense increased $12.4 million to $319.8 million for the nine months ended September 30, 2024, compared to $307.4 million during the nine months ended September 30, 2023, primarily due to increased interest expense of $24.2 million on the New Term Loans compared to the Existing Term Loans, and interest expense of $7.9 million on the Exchangeable Notes issued on July 22, 2024, partially offset by declines in interest expense of $17.4 million on the Second Lien Notes due to redemptions of principal balances and declines in interest expense related to the revolving credit facility of $1.8 million. See Note 6—Corporate Borrowings and Finance Lease Liabilities in the Notes to the Condensed Consolidated Financial Statements under Item 1 of Part I of this Form 10-Q for additional information about our indebtedness.

**Investment income.** Investment income was $14.4 million for the nine months ended September 30, 2024, compared to $11.4 million for the nine months ended September 30, 2023. Investment income in the current year includes interest income of $16.1 million and $0.2 million of increase in estimated fair value of our investment in common shares of Hycroft, partially offset by $1.9 million of decline in estimated fair value of our investment in warrants to purchase common shares of Hycroft. Investment income in the prior year includes a gain on sale of our 10.0% interest in Saudi Cinema Company, LLC of $15.5 million and interest income of $8.5 million, partially offset by $5.4 million of decline in estimated fair value of our investment in common shares of Hycroft and $5.4 million of decline in estimated fair value of our investment in warrants to purchase common shares of Hycroft and $1.8 million of expense for NCM Common Units.

**Income tax provision.** The income tax provision was $1.4 million and $4.6 million for the nine months ended September 30, 2024, and September 30, 2023, respectively. See Note 8—Income Taxes in the Notes to the Condensed Consolidated Financial Statements under Item 1 of Part I of this Form 10-Q for further information.

**Net loss.** Net loss was $217.0 million and $214.6 million during the nine months ended September 30, 2024, and September 30, 2023, respectively. Net loss during the nine months ended September 30, 2024 compared to net loss for the nine months ended September 30, 2023 was negatively impacted by the decrease in attendance as a result of the popularity of new film releases compared to the prior year and increases in interest expense, partially offset by decreases in rent expense, decreases in general and administrative expense, decreases in depreciation and amortization, increases in other income, increases in investment income and decreases in income tax provision.

### Theatrical Exhibition—U.S. Markets

**Revenues.** Total revenues decreased $295.5 million, or 10.3%, during the nine months ended September 30, 2024, compared to the nine months ended September 30, 2023. Admissions revenues decreased $178.4 million or 11.4%, during the nine months ended September 30, 2024, compared to the nine months ended September 30, 2023, primarily due to a decrease in attendance of 14.9% from 133.9 million patrons to 113.9 million patrons, partially offset by a 4.1% increase in average ticket price. The decrease in attendance was primarily due to the popularity of film product compared to the prior year. The availability and popularity of film product released during the nine months ended September 30, 2024, was negatively impacted by labor stoppages during 2023. The increase in average ticket price was primarily due to increased ticket prices for all formats, increases in IMAX and other PLF screen volumes as a percentage of attendance and increases in attendance for alternative content.

Food and beverage revenues decreased $103.6 million, or 9.8%, during the nine months ended September 30, 2024, compared to the nine months ended September 30, 2023, primarily due to the decrease in attendance, partially offset by an increase in food and beverage per patron. Food and beverage per patron increased 6.0% from $7.86 to $8.33 due primarily to an increase in average prices, partially offset by lower units purchase per transaction, a decline in the percentage of guests making transactions and more frequent attendance from our AMC Stubs members.

Total other theatre revenues decreased $13.5 million, or 5.6%, during the nine months ended September 30, 2024, compared to the nine months ended September 30, 2023, primarily due to the decline in attendance which resulted in lower ticket fees and advertising revenues.

**Operating costs and expenses.** Operating costs and expenses decreased $179.5 million, or 6.5%, during the nine months ended September 30, 2024, compared to the nine months ended September 30, 2023. Film exhibition costs decreased $104.9 million, or 12.8%, during the nine months ended September 30, 2024, compared to the nine months ended September 30, 2023, primarily due to the decrease in attendance and lower film rental terms. As a percentage of admissions revenues, film exhibition costs were 51.6% for the nine months ended September 30, 2024, compared to 52.4% for the nine months ended September 30, 2023. The decrease in film exhibition cost percentage is primarily due to the concentration of box office revenues in higher grossing films in the prior year, which typically results in higher film exhibition costs.

Food and beverage costs decreased $15.4 million, or 8.5%, during the nine months ended September 30, 2024, compared to the nine months ended September 30, 2023. The decrease in food and beverage costs was primarily due to the decrease in food and beverage revenues. As a percentage of food and beverage revenues, food and beverage costs were 17.5% for the nine months ended September 30, 2024, and 17.2% for the nine months ended September 30, 2023.

Operating expense decreased by $4.4 million, or 0.5%, during the nine months ended September 30, 2024, compared to the nine months ended September 30, 2023. The decrease in operating expense was primarily due to the decrease in attendance. As a percentage of revenues, operating expense was 36.2% for the nine months ended September 30, 2024, compared to 32.6% for the nine months ended September 30, 2023. Rent expense increased 0.8%, or $4.0 million, during the nine months ended September 30, 2024, compared to the nine months ended September 30, 2023, primarily due to the early termination of one theatre lease for a benefit of $16.7 million in the prior year, which included an early termination payment from the landlord for $13.0 million.

**Merger, acquisition, and other costs.** Merger, acquisition, and other costs were $0.1 million during the nine months ended September 30, 2024, compared to $1.4 million during the nine months ended September 30, 2023.

**Other.** Other general and administrative expense decreased $25.8 million, or 19.7%, during the nine months ended September 30, 2024, compared to the nine months ended September 30, 2023, due primarily to declines in stock-based compensation expense and lower bonus expense, as a result of lower annual performance compared to annual targets in the current year compared to the prior year. We recorded $1.9 million of stock-based compensation expense during the nine months ended September 30, 2024 compared to $18.1 million during the nine months ended September

30, 2023 related to special awards in each year accounted for as a modification to the respective 2023 and 2022 PSU awards which lowered the Adjusted EBITDA and free cash flow performance targets such that 200% vesting was achieved for both tranches in 2023 and 2022. See Note 7—Stockholders’ Deficit in the Notes to the Condensed Consolidated Financial Statements under Item 1 of Part I of this Form 10-Q for additional information about stock-based compensation expense.

**Depreciation and amortization.** Depreciation and amortization decreased $31.7 million, or 14.5%, during the nine months ended September 30, 2024, compared to the nine months ended September 30, 2023, primarily due to theatre closures and lower depreciation expense on theatres impaired during the year ended December 31, 2023.

**Other income.** Other income of $117.9 million during the nine months ended September 30, 2024 was primarily due to $73.5 million of income related to the decrease in fair value of the Conversion Option derivative liability, a gain on extinguishment of debt of $38.5 million related to the redemption of $805.0 million aggregate principal amount of the Second Lien Notes, $34.0 million of recoveries related to the Shareholder Litigation, $10.1 million of equity in earnings of non-consolidated entities and $3.6 million of other settlement proceeds, partially offset by $41.0 million of third party costs related to the modification of the Existing Term Loans. Other income of $5.6 million during the nine months ended September 30, 2023 was primarily due to a gain on extinguishment of debt of $95.2 million related to the redemption of $165.6 million aggregate principal amount of the Second Lien Notes, a gain on extinguishment of debt of $2.3 million related to the redemption of $4.1 million aggregate principal amount of our Senior Subordinated Notes due 2026, a receipt of $14.0 million in settlement of the Lao Action and equity in earnings of non-consolidated entities of $3.8 million, partially offset by $110.1 million of expense related to the settlement of the Shareholder Litigation comprised of $10.8 million of estimated legal fees and contingent insurance recovery costs and $99.3 million of non-cash expense for the estimated fair value as of the date of the final Delaware Supreme Court order of settlement shares issued to holders of Common Stock on August 28, 2023. See Note 1—Basis of Presentation in the Notes to the Condensed Consolidated Financial Statements under Item 1 of Part I of this Form 10-Q for additional information about the components of other expense (income).

**Interest expense.** Interest expense increased $11.7 million to $272.5 million for the nine months ended September 30, 2024, compared to $260.8 million during the nine months ended September 30, 2023, primarily due to increased interest expense of $24.2 million on the New Term Loans compared to the Existing Term Loans, and interest expense of $7.9 million on the Exchangeable Notes issued on July 22, 2024, partially offset by declines in interest expense of $17.4 million on the Second Lien Notes due to redemptions of principal balances and declines in interest expense related to the revolving credit facility of $1.8 million. See Note 6—Corporate Borrowings and Finance Lease Liabilities in the Notes to the Condensed Consolidated Financial Statements under Item 1 of Part I of this Form 10-Q for additional information about our indebtedness.

**Investment expense (income).** Investment income was $(13.0) million for the nine months ended September 30, 2024, compared to expense of $4.7 million for the nine months ended September 30, 2023. Investment income in the current year includes interest income of $(14.7) million and $(0.2) million of increase in the estimated fair value of our investment in common shares of Hycroft, partially offset by $1.9 million of decrease in estimated fair value of our investment in warrants to purchase common shares of Hycroft. Investment expense in the prior year includes $5.4 million of decline in estimated fair value of our investment in common shares of Hycroft, $5.4 million of decline in estimated fair value of our investment in warrants to purchase common shares of Hycroft and $1.8 million of expense for NCM Common Units, partially offset by interest income of $7.9 million.

**Income tax provision (benefit).** The income tax benefit was $(0.7) million and provision $1.6 million for the nine months ended September 30, 2024, and September 30, 2023, respectively. See Note 8—Income Taxes in the Notes to the Condensed Consolidated Financial Statements under Item 1 of Part I of this Form 10-Q for further information.

**Net loss.** Net loss was $166.4 million and $171.0 million during the nine months ended September 30, 2024, and September 30, 2023, respectively. Net loss during the nine months ended September 30, 2024, compared to net loss for the nine months ended September 30, 2023, were positively impacted by decreases in general and administrative expense, depreciation and amortization, increases in other income, decreases in investment expense and the decrease in income tax provision, partially offset by the decrease in attendance as a result of the popularity of new film releases compared to the prior year, increases in rent expense and increases in interest expense.

### Theatrical Exhibition—International Markets

**Revenues.** Total revenues decreased $81.9 million, or 9.6%, during the nine months ended September 30, 2024, compared to the nine months ended September 30, 2023. Admissions revenues decreased $58.4 million, or 11.3%, during the nine months ended September 30, 2024, compared to the nine months ended September 30, 2023, primarily due to a decrease in attendance of 10.9% from 53.7 million patrons to 47.8 million patrons and a decrease in average ticket price of 0.5%. The decrease in attendance was primarily due to the popularity of film product compared to the prior year.

Food and beverage revenues decreased $17.3 million, or 7.0%, during the nine months ended September 30, 2024, compared to the nine months ended September 30, 2023, primarily due to the decrease in attendance, partially offset by an increase in food and beverage per patron. Food and beverage per patron increased 4.3% from $4.61 to $4.81 primarily due to an increase in average prices and the percentage of guests making transactions.

Total other theatre revenues decreased $6.2 million, or 6.9%, during the nine months ended September 30, 2024, compared to the nine months ended September 30, 2023, primarily due to the decline in attendance which resulted in lower ticket fees and advertising revenues.

**Operating costs and expenses.** Operating costs and expenses decreased $37.9 million, or 4.4%, during the nine months ended September 30, 2024, compared to the nine months ended September 30, 2023. Film exhibition costs decreased $29.9 million, or 14.2%, during the nine months ended September 30, 2024, compared to the nine months ended September 30, 2023, primarily due to the decrease in attendance and lower film rental terms. As a percentage of admissions revenues, film exhibition costs were 39.4% for the nine months ended September 30, 2024, compared to 40.8% for the nine months ended September 30, 2023. The decrease in film exhibition cost percentage is primarily due to the concentration of box office revenues in higher grossing films in the prior year, which typically results in higher film exhibition costs.

Food and beverage costs decreased $5.2 million, or 8.4%, during the nine months ended September 30, 2024, compared to the nine months ended September 30, 2023. The decrease in food and beverage costs was primarily due to the decrease in food and beverage revenues. As a percentage of food and beverage revenues, food and beverage costs were 24.7% for the nine months ended September 30, 2024, compared to 25.1% for the nine months ended September 30, 2023.

Operating expense decreased by $2.7 million, or 0.9%, during the nine months ended September 30, 2024, compared to the nine months ended September 30, 2023. The decrease in operating expense was primarily due to lower utilities expense and the decrease in attendance. As a percentage of revenues, operating expense was 40.5% for the nine months ended September 30, 2024, compared to 36.9% for the nine months ended September 30, 2023. Rent expense increased 2.7%, or $4.5 million, during the nine months ended September 30, 2024, compared to the nine months ended September 30, 2023.

**Other.** Other general and administrative expense increased $1.7 million, or 3.2%, during the nine months ended September 30, 2024, compared to the nine months ended September 30, 2023.

**Depreciation and amortization.** Depreciation and amortization decreased $6.2 million, or 10.3%, during the nine months ended September 30, 2024, compared to the nine months ended September 30, 2023, primarily due to theatre closures and lower depreciation expense on theatres impaired during the year ended December 31, 2023.

**Other income.** Other income of $55.9 million during the nine months ended September 30, 2024, was primarily due to the favorable settlement of a vendor dispute of $36.2 million, and foreign currency transaction gains of $19.0 million. Other income of $4.4 million during the nine months ended September 30, 2023, was primarily due to $3.2 million in foreign currency transaction gains. See Note 1—Basis of Presentation in the Notes to the Condensed Consolidated Financial Statements under Item 1 of Part I of this Form 10-Q for additional information about the components of other expense (income).

**Interest expense.** Interest expense increased by $0.7 million for the nine months ended September 30, 2024, compared to the nine months ended September 30, 2023. See Note 6—Corporate Borrowings and Finance Lease Liabilities in the Notes to the Condensed Consolidated Financial Statements under Item 1 of Part I of this Form 10-Q for additional information about our indebtedness.

**Investment income.** Investment income was $1.4 million for the nine months ended September 30, 2024, and $16.1 million for the nine months ended September 30, 2023. Investment income in the current year includes $1.4 million of interest income. Investment income in the prior year includes a gain on sale of our 10.0% interest in Saudi Cinema Company, LLC of $(15.5) million and interest income of $(0.6) million.

**Income tax provision.** The income tax provision was $2.1 million and $3.0 million for the nine months ended September 30, 2024, and September 30, 2023, respectively. See Note 8—Income Taxes in the Notes to the Condensed Consolidated Financial Statements under Item 1 of Part I of this Form 10-Q for further information.

**Net loss.** Net loss was $50.6 million and $43.6 million during the nine months ended September 30, 2024, and September 30, 2023, respectively. Net loss during the nine months ended September 30, 2024 compared to net loss for the nine months ended September 30, 2023 was negatively impacted by the decrease in attendance as a result of the popularity of new film releases compared to the prior year, increases in rent expense, increases in general and administrative expenses, increases in interest expense and decreases in investment income, partially offset by decreases in depreciation and amortization expense, increases in other income and decreases in income tax provision.

### Adjusted EBITDA

We present Adjusted EBITDA as a supplemental measure of our performance. We define Adjusted EBITDA as net earnings (loss) plus (i) income tax provision (benefit), (ii) interest expense and (iii) depreciation and amortization, as further adjusted to eliminate the impact of certain items that we do not consider indicative of our ongoing operating performance and to include attributable EBITDA from equity investments in theatre operations in International markets. These further adjustments are itemized below. You are encouraged to evaluate these adjustments and the reasons we consider them appropriate for supplemental analysis. In evaluating Adjusted EBITDA, you should be aware that in the future we may incur expenses that are the same as or similar to some of the adjustments in this presentation. Our presentation of Adjusted EBITDA should not be construed as an inference that our future results will be unaffected by unusual or non-recurring items. The preceding definition of and adjustments made to GAAP measures to determine Adjusted EBITDA are broadly consistent with Adjusted EBITDA as defined in the Company’s debt indentures. During the three months ended September 30, 2024, the Company changed the definition of Adjusted EBITDA to no longer further adjust for “cash distributions from non-consolidated entities” and “other non-cash rent benefit.” All comparative period information for Adjusted EBITDA has been re-cast to conform with the current definition.

The following tables set forth our Adjusted EBITDA by reportable operating segment and our reconciliation of Adjusted EBITDA:

| ​ ​ Adjusted EBITDA (In millions) | ​ ​ ​ | ​ ​ Three Months Ended September 30, 2024 | ​ | ​ ​ September 30, 2023 | ​ ​ ​ | ​ ​ Nine Months Ended September 30, 2024 | ​ | ​ ​ September 30, 2023 |
| --- | --- | ---: | --- | ---: | --- | ---: | --- | ---: |
| U.S. markets | ​ | $143.3 | ​ | $155.5 | ​ | $178.5 | ​ | $353.4 |
| International markets | ​ | ​ 18.5 | ​ | ​ 44.4 | ​ | ​ 0.6 | ​ | ​ 53.0 |
| Total Adjusted EBITDA | ​ | $161.8 | ​ | $199.9 | ​ | $179.1 | ​ | $406.4 |

*(In millions)*

| ​ ​ | ​ ​ ​ | ​ ​ Three Months Ended September 30, 2024 | ​ ​ | ​ ​ September 30, 2023 | ​ ​ | ​ ​ Nine Months Ended September 30, 2024 | ​ ​ | ​ ​ September 30, 2023 |
| --- | --- | ---: | --- | ---: | --- | ---: | --- | ---: |
| Net earnings (loss) | ​ | $(20.7) | ​ | $12.3 | ​ | $(217.0) | ​ | $(214.6) |
| Plus: | ​ | ​ ​ | ​ | ​ ​ | ​ | ​ ​ | ​ | ​ ​ |
| Income tax provision (benefit) (1) | ​ | (1.1) | ​ | 2.3 | ​ | 1.4 | ​ | 4.6 |
| Interest expense | ​ | 119.6 | ​ | 103.7 | ​ | 319.8 | ​ | 307.4 |
| Depreciation and amortization | ​ | 80.8 | ​ | 88.7 | ​ | 241.2 | ​ | 279.1 |
| Certain operating expense (2) | ​ | 2.0 | ​ | 3.8 | ​ | 3.5 | ​ | 4.0 |
| Equity in earnings of non-consolidated entities (3) | ​ | (5.2) | ​ | (3.1) | ​ | (9.9) | ​ | (5.3) |
| Attributable EBITDA (4) | ​ | ​ 1.3 | ​ | ​ 1.4 | ​ | ​ 1.2 | ​ | ​ 1.6 |
| Investment income (5) | ​ | (3.2) | ​ | (3.0) | ​ | (14.4) | ​ | (11.4) |
| Other income (6) | ​ | (18.1) | ​ | (14.1) | ​ | (161.9) | ​ | (1.4) |
| General and administrative — unallocated: | ​ | ​ ​ | ​ | ​ ​ | ​ | ​ ​ | ​ | ​ ​ |
| Merger, acquisition and other costs (7) | ​ | 0.1 | ​ | 0.7 | ​ | 0.1 | ​ | 1.5 |
| Stock-based compensation expense (8) | ​ | 6.3 | ​ | 7.2 | ​ | 15.1 | ​ | 40.9 |
| Adjusted EBITDA | ​ | $161.8 | ​ | $199.9 | ​ | $179.1 | ​ | $406.4 |

(1) For information regarding the income tax provision, see Note 8—Income Taxes in the Notes to the Condensed Consolidated Financial Statements under Item 1 of Part I of this Form 10-Q.

(2) Amounts represent preopening expense related to temporarily closed screens under renovation, theatre and other closure expense for the permanent closure of screens, including the related accretion of interest, disposition of assets and other non-operating gains or losses included in operating expenses. We have excluded these items as they are non-cash in nature or are non-operating in nature.

(3) Equity in earnings of non-consolidated entities during the three months ended September 30, 2024 primarily consisted of equity in earnings from AC JV of $(4.3) million. Equity in earnings of non-consolidated entities during the three months ended September 30, 2023 primarily consisted of equity in earnings from AC JV of $(1.5) million.

Equity in earnings of non-consolidated entities during the nine months ended September 30, 2024 primarily consisted of equity in earnings from AC JV of $(9.5) million. Equity in earnings of non-consolidated entities during the nine months ended September 30, 2023 primarily consisted of equity in earnings from AC JV of $(3.4) million.

(4) Attributable EBITDA includes the EBITDA from equity investments in theatre operators in certain International markets. See below for a reconciliation of our equity in loss of non-consolidated entities to attributable EBITDA. Because these equity investments are in theatre operators in regions where we hold a significant market share, we believe attributable EBITDA is more indicative of the performance of these equity investments and management uses this measure to monitor and evaluate these equity investments. We also provide services to these theatre operators including information technology systems, certain on-screen advertising services and our gift card and package ticket program.

*(In millions)*

| ​ ​ | ​ ​ ​ | ​ ​ Three Months Ended September 30, 2024 | ​ ​ | ​ ​ September 30, 2023 | ​ ​ | ​ ​ Nine Months Ended September 30, 2024 | ​ ​ | ​ ​ September 30, 2023 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Equity in (earnings) of non-consolidated entities | ​ | $(5.2) | ​ | $(3.1) | ​ | $(9.9) | ​ | $(5.3) |
| Less: | ​ | ​ ​ | ​ | ​ ​ | ​ | ​ ​ | ​ | ​ ​ |
| Equity in (earnings) of non-consolidated entities excluding International theatre joint ventures | ​ | ​ (4.7) | ​ | ​ (2.1) | ​ | ​ (10.3) | ​ | ​ (4.7) |
| Equity in earnings (loss) of International theatre joint ventures | ​ | ​ 0.5 | ​ | ​ 1.0 | ​ | ​ (0.4) | ​ | ​ 0.6 |
| Income tax provision (benefit) | ​ | ​ — | ​ | ​ 0.1 | ​ | ​ (0.1) | ​ | ​ (0.1) |
| Investment income | ​ | ​ (0.1) | ​ | ​ (0.2) | ​ | ​ — | ​ | ​ (0.1) |
| Interest expense | ​ | ​ — | ​ | ​ 0.1 | ​ | ​ 0.1 | ​ | ​ 0.2 |
| Depreciation and amortization | ​ | ​ 0.7 | ​ | ​ 0.4 | ​ | ​ 1.4 | ​ | ​ 1.0 |
| Other expense | ​ | ​ 0.2 | ​ | ​ — | ​ | ​ 0.2 | ​ | ​ — |
| Attributable EBITDA | ​ | $1.3 | ​ | $1.4 | ​ | $1.2 | ​ | $1.6 |

(5) Investment expense (income) during the three months ended September 30, 2024 includes appreciation in estimated fair value of our investment in common shares of Hycroft of $(0.3) million, deterioration in estimated fair value of our investment in warrants to purchase common shares of Hycroft of $1.7 million and interest income of $(4.6) million. Investment expense (income) during the three months ended September 30, 2023 included appreciation in estimated fair value of our investment in common shares of Hycroft of $(0.1) million, deterioration in estimated fair value of our investment in warrants to purchase common shares of Hycroft of $0.8 million, and interest income of $(3.7) million.

Investment expense (income) during the nine months ended September 30, 2024 includes appreciation in estimated fair value of our investment in common shares of Hycroft of $(0.2) million, deterioration in estimated fair value of our investment in warrants to purchase common shares of Hycroft of $1.9 million, and interest income of $(16.1) million. Investment expense (income) during the nine months ended September 30, 2023 included deterioration in estimated fair value of our investment in common shares of Hycroft of $5.4 million, deterioration in estimated fair value of our investment in warrants to purchase common shares of Hycroft of $5.4 million, $1.8 million of expense for NCM Common Units, $(15.5) million gain on the sale of our investment in Saudi Cinema Company, LLC and interest income of $(8.5) million.

(6) Other expense (income) during the three months ended September 30, 2024 includes shareholder litigation recoveries of $(14.9) million, foreign currency transaction gains of $(21.5) million, losses on debt extinguishment of $50.8 million, term loan modification third party fees of $41.0 million, and a decrease in fair value of the derivative liability for the embedded conversion feature in the Exchangeable Notes of $(73.5) million. Other expense (income) during the three months ended September 30, 2023 included a non-cash litigation contingency adjustment of $(16.1) million, foreign currency transaction losses of $12.8 million, and gains on debt extinguishment of $(10.8) million.

Other expense (income) during the nine months ended September 30, 2024 includes shareholder litigation recoveries of $(34.0) million, gains on debt extinguishment of $(40.3) million, term loan modification third party fees of $41.0 million, a vendor dispute settlement of $(36.2) million, foreign currency transaction gains of $(18.9) million and a decrease in fair value of the derivative liability for the embedded conversion feature in the Exchangeable Notes of $(73.5) million. Other expense (income) during the nine months ended September 30, 2023 included a non-cash litigation contingency charge of $99.3 million, partially offset by gains on debt extinguishment of $(97.5) million and foreign currency transaction gains of $(3.2) million.

(7) Merger, acquisition and other costs are excluded as they are non-operating in nature.

(8) Non-cash expense included in general and administrative: other.

Adjusted EBITDA is a non-GAAP financial measure commonly used in our industry and should not be construed as an alternative to net earnings (loss) as an indicator of operating performance (as determined in accordance with U.S. GAAP). Adjusted EBITDA may not be comparable to similarly titled measures reported by other companies. We have included Adjusted EBITDA because we believe it provides management and investors with additional information to measure our performance and estimate our value.

Adjusted EBITDA has important limitations as an analytical tool, and you should not consider it in isolation, or as a substitute for analysis of our results as reported under U.S. GAAP. For example, Adjusted EBITDA:

- does not reflect our capital expenditures, future requirements for capital expenditures or contractual commitments;
- does not reflect changes in, or cash requirements for, our working capital needs;
- does not reflect the significant interest expenses, or the cash requirements necessary to service interest or principal payments on our debt;
- excludes income tax payments that represent a reduction in cash available to us; and
- does not reflect any cash requirements for the assets being depreciated and amortized that may have to be replaced in the future.

During the three months ended September 30, 2024, Adjusted EBITDA in the U.S. markets was $143.3 million compared to $155.5 million during the three months ended September 30, 2023. The year-over-year decline was primarily driven by a decrease in attendance partially due to a decline in market share of box office revenues compared to the prior year driven by the interplay between the film slate and our geographic mix, increases in film exhibition cost as a percentage of admissions revenue, and increases in operating expenses. These declines were partially offset by increases in average ticket price, increases in food and beverage sales per patron, decreases in rent expense and decreases in general and administrative expenses. During the three months ended September 30, 2024, Adjusted EBITDA in the International markets was $18.5 million compared to $44.4 million during the three months ended September 30, 2023. The year-over-year decline was primarily driven by a decrease in attendance as a result of the popularity of new film releases compared to the prior year and declines in average ticket price. These declines were partially offset by increases in food and beverage sales per patron and decreases in rent expense. During the three months ended September 30, 2024, Adjusted EBITDA in the U.S. markets and International markets was $161.8 million compared to $199.9 million during the three months ended September 30, 2023, driven by the aforementioned factors impacting Adjusted EBITDA.

During the nine months ended September 30, 2024, Adjusted EBITDA in the U.S. markets was $178.5 million compared to $353.4 million during the nine months ended September 30, 2023. The year-over-year decline was primarily driven by a decrease in attendance as a result of the availability and popularity of new film releases compared to the prior year and increases in rent expense due to a prior year rent credit for a theatre termination. These declines were partially offset by increases in average ticket price, increases in food and beverage sales per patron and decreases in general and administrative expenses. During the nine months ended September 30, 2024, Adjusted EBITDA in the International markets was $0.6 million compared to $53.0 million during the nine months ended September 30, 2023. The year-over-year decline was primarily driven by a decrease in attendance as a result of the popularity of new film releases compared to the prior year, declines in average ticket price and increases in rent expense. During the nine months ended September 30, 2024, Adjusted EBITDA in the U.S. markets and International markets was $179.1 million compared to $406.4 million during the nine months ended September 30, 2023, driven by the aforementioned factors impacting Adjusted EBITDA.

### LIQUIDITY AND CAPITAL RESOURCES

Our consolidated revenues are primarily collected in cash, principally through admissions and food and beverage sales. We have an operating “float” which partially finances our operations and which generally permits us to maintain a smaller amount of working capital capacity. This float exists because admissions revenues are received in cash, while exhibition costs (primarily film rentals) are ordinarily paid to distributors 20 to 45 days following receipt of admissions revenues. Film distributors generally release the films which they anticipate will be the most successful during the summer and year-end holiday seasons. Consequently, we typically generate higher revenues during such periods and experience higher working capital requirements following such periods.

We had working capital deficit (excluding restricted cash) as of September 30, 2024, and December 31, 2023 of ($839.5) million and $(456.4) million, respectively. As of September 30, 2024 and December 31, 2023, working capital included operating lease liabilities of $527.6 million and $508.8 million, respectively, and deferred revenues of $385.1 million and $421.8 million, respectively.

See Note 6—Corporate Borrowings and Finance Lease Liabilities in the Notes to the Condensed Consolidated Financial Statements under Item 1 of Part I of this Form 10-Q for a further discussion of our Financial Covenants.

As of September 30, 2024, we had cash and cash equivalents of $527.4 million.

We have continued to lower the future interest expense of our fixed-rate debt through debt buybacks and exchanges for equity and enhanced liquidity through equity issuances. See Note 6—Corporate Borrowings and Finance Lease Liabilities, Note 7—Stockholders’ Deficit, and Note 13—Subsequent Events in the Notes to the Condensed Consolidated Financial Statements under Item 1 of Part I of this Form 10-Q for further information.

We expect, from time to time, to continue to seek to retire or purchase our outstanding debt through cash purchases and/or exchanges for equity or debt, in open-market purchases, privately negotiated transactions or otherwise. Such repurchases or exchanges, if any, will be upon such terms and at such prices as we may determine, and will depend on prevailing market conditions, our liquidity requirements, contractual restrictions and other factors. The amounts involved may be material and, to the extent equity is used, dilutive.

### Refinancing Transactions

On July 22, 2024, we completed a series of refinancing transactions (the “Refinancing Transactions”) with two creditor groups to refinance and extend to 2029 and 2030 the maturities of approximately $1.6 billion of our debt previously maturing in 2026.

On August 1, 2024, we completed follow-on open market repurchases of our Existing Term Loans, and in exchange, issued to such selling holders our New Term Loans pursuant to the New Term Loan Credit Agreement of approximately $762.0 million.

On August 14, 2024, we completed an additional follow-on open market repurchase of our Existing Term Loans, and in exchange, issued to such selling holders our New Term Loans pursuant to the New Term Loan Credit Agreement of approximately $4.0 million.

On September 17, 2024, we issued $27.0 million of New Term Loans at par for cash and used the proceeds to redeem the remaining Existing Term Loans. As of September 30, 2024, the Company completed open market purchases of $1,895.0 million aggregate principal amount of its Existing Term Loans and issued $2,024.3 million aggregate principal amount of the New Term Loans. Accordingly, as of such date, the Company had no remaining aggregate principal amount of Existing Term Loans outstanding.

See Note 6—Corporate Borrowings and Finance Lease Liabilities in the Notes to the Condensed Consolidated Financial Statements under Item 1 of Part I of this Form 10-Q for further information.

### Liquidity Requirements

We believe our existing cash and cash equivalents, together with cash generated from operations, will be sufficient to fund our operations and satisfy our obligations currently and through the next twelve months. Our current cash burn rates are not sustainable long-term. In order to achieve sustainable net positive cash flows provided by operating activities and long-term profitability, we believe that revenues will need to increase to levels at least in line with pre-COVID-19 revenues. North American box office grosses were down approximately 25% for the nine months ended September 30, 2024, compared to the nine months ended September 30, 2019. Until such time as we are able to achieve sustainable net positive cash flows provided by operating activities, it is difficult to estimate our future cash burn rates and liquidity requirements. Depending on our assumptions regarding the timing and ability to achieve levels of revenue, the estimates of amounts of required liquidity vary significantly.

There can be no assurance that the revenues, attendance levels and other assumptions used to estimate our liquidity requirements and future cash burn rates will be correct, and our ability to be predictive is uncertain due to limited ability to predict studio film release dates, the overall production and theatrical release levels and success of individual titles. Additionally, the effects of labor stoppages that occurred during 2023 had a negative impact in 2024 on the film slate for exhibition, the Company’s liquidity and cash burn rates. Further, there can be no assurances that we will be successful in generating the additional liquidity necessary to meet our obligations beyond twelve months from the issuance of this Quarterly Report on terms acceptable to us or at all.

On March 28, 2024, we entered into a Common Stock equity distribution agreement with certain sales agents to sell shares of Common Stock, from time to time, having an aggregate offering price of $250.0 million, through an at-the-market offering program. During the nine months ended September 30, 2024, we raised gross proceeds of $250.0 million and paid fees to sales agents and incurred other third-party issuance costs of approximately $6.3 million and $0.6 million, respectively, through the at-the-market offering of approximately 72.5 million shares of Common Stock. We paid $0.7 million of other third-party issuance costs during the nine months ended September 30, 2024. We intend to use any net proceeds from the sale of Common Stock pursuant to the program to bolster liquidity, to repay, refinance, redeem or repurchase our existing indebtedness (including expenses, accrued interest and premium, if any) and for general corporate purposes.

As of April 19, 2024, and in anticipation of the maturity of the Senior Secured Revolving Credit Facility, we voluntarily terminated the commitments under the Senior Secured Revolving Credit Facility in full and paid off any remaining obligations with respect to the Senior Secured Revolving Credit Facility. We currently do not expect to replace the Senior Secured Revolving Credit Facility. We have entered into a new letter of credit facility in order to continue to provide letters of credit in the ordinary course of business following the termination of the Senior Secured Revolving Credit Facility.

### Cash Flows from Operating Activities

Net cash flows used in operating activities, as reflected in the condensed consolidated statements of cash flows, were $254.4 million and $137.4 million during the nine months ended September 30, 2024 and September 30, 2023, respectively. The increase in net cash flows used in operating activities was primarily due to the decline in attendance due to the impact of labor stoppages that occurred during 2023 and third-party fees paid in connection with the modification of the term loans. All things being equal, a decline in attendance results in less cash inflows provided by operating activities that could be used to pay for the costs associated with our operations, thus creating an increase in net cash used in operations. The additional cash used in operating activities due to the decline in attendance was partially offset by reductions in rent repayments that were deferred during the COVID-19 pandemic and vendor dispute and other settlement proceeds received during the nine months ended September 30, 2024.

### Cash Flows from Investing Activities

Net cash flows used in investing activities, as reflected in the condensed consolidated statements of cash flows, were $154.0 million and $116.4 million during the nine months ended September 30, 2024 and September 30, 2023, respectively. Cash outflows from investing activities include capital expenditures of $155.8 million and $153.5 million during the nine months ended September 30, 2024, and September 30, 2023, respectively.

During the nine months ended September 30, 2023, cash flows used in investing activities included proceeds from the sale of our investment in Saudi Cinema Company, LLC of $30.0 million and proceeds from the disposition of long-term assets of $8.6 million.

We fund the costs of constructing, maintaining, and remodeling our theatres through existing cash balances, cash generated from operations, landlord contributions, or capital raised, as necessary. We generally lease our theatres pursuant to long-term non-cancelable operating leases, which may require the developer, who owns the property, to reimburse us for the construction costs. We estimate that our capital expenditures, net of landlord contributions, will be approximately $175 million to $225 million for year ended December 31, 2024, to maintain and enhance operations.

### Cash Flows from Financing Activities

Net cash flows provided by financing activities, as reflected in the condensed consolidated statements of cash flows, were $72.1 million and $355.3 million during the nine months ended September 30, 2024 and September 30, 2023, respectively. Cash flows provided by financing activities during the nine months ended September 30, 2024, were primarily due to net proceeds from equity issuances of $243.0 million and proceeds from the issuance of New Term Loans of $27.0 million, partially offset by the repurchase of Second Lien Notes of $83.2 million, deferred debt issuance costs of $45.7 million, principal payments under Existing Term Loans of $27.0 million, the repurchase of Senior Subordinated Notes due 2025 of $12.9 million, the repurchase of Senior Subordinated Notes due 2026 of $6.0 million, principal payments under term loan borrowings of $15.1 million, and taxes paid for restricted unit withholdings of $2.2 million. See Note 6—Corporate Borrowings and Finance Lease Liabilities and Note 7—Stockholders’ Equity in the Notes to the condensed consolidated financial statements in Item 1 of Part I of this Form 10-Q for further information, including a summary of principal payments required and maturities of corporate borrowings as of September 30, 2024.

Cash flows provided by financing activities during the nine months ended September 30, 2023, were primarily due to net proceeds from equity issuances of $492.4 million, net of issuance costs, partially offset by the repurchase of Second Lien Notes for $99.8 million, and taxes paid for restricted unit withholdings of $14.2 million.

### Formation of Unrestricted Subsidiaries

On July 22, 2024, American-Multi Cinema Inc. (“Multi-Cinema”), a Missouri corporation and a direct subsidiary of AMC Entertainment Holdings, Inc. (“Holdings”), assigned or transferred the net assets (“Theatre Net Assets”) of 175 theatres and transferred a 100% interest in certain intellectual property assets to its direct subsidiary Centertainment Development, LLC (“Centertainment”), and the Theatre Net Assets were in turn transferred to Centertainment’s direct wholly-owned subsidiary Muvico, LLC (“Muvico”), a newly formed Texas limited liability company. Theatre Net Assets include lease contracts and theatre property, including furniture, fixtures, plant and equipment, and other working capital items associated directly with the theatre locations. At the same time, Muvico licensed the intellectual property back to Multi-Cinema for its continued use in the operation of its retained theatres and entered into a management agreement for Multi-Cinema to operate the theatres transferred to Muvico. Muvico and Centertainment (collectively, the “Muvico Group”) are unrestricted subsidiaries under the indenture governing Holdings’ Existing First Lien Notes.

### Unrestricted Subsidiaries’ Financial Information and Operating Metrics

Pursuant to the indenture governing Holdings’ Existing First Lien Notes, the indenture governing Muvico’s Exchangeable Notes, and the New Term Loan Credit Agreement governing Holdings’ and Muvico’s New Term Loans, we are presenting the following financial information and operating metrics for the Muvico Group separately from Holdings and its restricted subsidiaries (the “Restricted Subsidiaries” and collectively with Holdings, the “AMC Group”). AMC Theatres of UK Limited, which is an unrestricted subsidiary under the indenture governing Holdings’ Existing First Lien Notes has been included with the Restricted Subsidiaries for the purposes of the following presentation of financial information and operating metrics (this subsidiary is individually immaterial). The financial information presented for AMC Group and Muvico Group is presented on a standalone basis with discrete identification of the assets, liabilities, revenues and expenses associated with the Theatre Net Assets that were transferred to Muvico. Intercompany transactions between entities within the AMC Group or within the Muvico Group have been eliminated. Certain entities within the AMC Group and within the Muvico Group are parties to intercompany management, licensing, and debt agreements with each other. These transactions are reflected discretely within the columnar presentation below and are properly eliminated upon consolidation. The financial information is also prepared using the historical cost carrying values of Holdings, the top parent entity.

Holdings and Muvico are co-borrowers and joint and severally liable for the New Term Loan borrowings. Pursuant to ASC 405-40 we have allocated fifty percent (50%) of the liabilities, interest expense and cash flows each to Muvico and Holdings, respectively. The basis of this allocation is the amount we expect each party to pay.

*(In millions)*

*(unaudited)*

*(unaudited)*

*(unaudited)*

*(unaudited)*

| ​ ​ ​ ​ ​ ​ Revenues | ​ ​ ​ ​ ​ ​ ​ | ​ ​ Three Months Ended September 30, 2024 AMCEH & Restricted Subsidiaries/AMC Group (1) ​ ​ | ​ ​ ​ ​ ​ ​ ​ | ​ ​ ​ ​ Muvico Group Unrestricted Subsidiaries (2) ​ ​ | ​ ​ ​ ​ ​ ​ ​ | ​ ​ ​ ​ ​ ​ Eliminations ​ ​ | ​ ​ ​ ​ ​ ​ ​ | ​ ​ ​ ​ ​ ​ ​ Consolidated ​ ​ |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Admissions | ​ | $577.3 | ​ | $166.9 | ​ | $— | ​ | $744.2 |
| Food and beverage | ​ | ​ 400.3 | ​ | ​ 90.1 | ​ | ​ — | ​ | ​ 490.4 |
| Other theatre (4) | ​ | ​ 101.9 | ​ | ​ 20.4 | ​ | ​ (8.1) | ​ | ​ 114.2 |
| Total revenues | ​ | ​ 1,079.5 | ​ | ​ 277.4 | ​ | ​ (8.1) | ​ | ​ 1,348.8 |
| Operating costs and expenses | ​ | ​ ​ | ​ | ​ ​ | ​ | ​ ​ | ​ | ​ ​ |
| Film exhibition costs | ​ | ​ 291.8 | ​ | ​ 89.6 | ​ | ​ — | ​ | ​ 381.4 |
| Food and beverage costs | ​ | ​ 74.6 | ​ | ​ 15.1 | ​ | ​ — | ​ | ​ 89.7 |
| Operating expense, excluding depreciation and amortization below | ​ | ​ 362.4 | ​ | ​ 92.2 | ​ | ​ — | ​ | ​ 454.6 |
| Rent | ​ | ​ 173.7 | ​ | ​ 42.7 | ​ | ​ — | ​ | ​ 216.4 |
| General and administrative: | ​ | ​ ​ | ​ | ​ ​ | ​ | ​ ​ | ​ | ​ ​ |
| Merger, acquisition and other costs | ​ | ​ 0.1 | ​ | ​ — | ​ | ​ — | ​ | ​ 0.1 |
| Other, excluding depreciation and amortization below (4) | ​ | ​ 57.9 | ​ | ​ 4.2 | ​ | ​ (8.1) | ​ | ​ 54.0 |
| Depreciation and amortization | ​ | ​ 65.7 | ​ | ​ 15.1 | ​ | ​ — | ​ | ​ 80.8 |
| Operating costs and expenses | ​ | ​ 1,026.2 | ​ | ​ 258.9 | ​ | ​ (8.1) | ​ | ​ 1,277.0 |
| Operating income | ​ | ​ 53.3 | ​ | ​ 18.5 | ​ | ​ — | ​ | ​ 71.8 |
| Other expense, net: | ​ | ​ ​ | ​ | ​ ​ | ​ | ​ ​ | ​ | ​ ​ |
| Other expense (income), net | ​ | ​ 50.7 | ​ | ​ (73.5) | ​ | ​ — | ​ | ​ (22.8) |
| Interest expense: | ​ | ​ ​ | ​ | ​ ​ | ​ | ​ ​ | ​ | ​ ​ |
| Corporate borrowings | ​ | ​ 77.6 | ​ | ​ 32.0 | ​ | ​ — | ​ | ​ 109.6 |
| Finance lease obligations | ​ | ​ 1.0 | ​ | ​ — | ​ | ​ — | ​ | ​ 1.0 |
| Intercompany interest expense | ​ | ​ — | ​ | ​ 3.2 | ​ | ​ (3.2) | ​ | ​ — |
| Non-cash NCM exhibitor services agreement | ​ | ​ 9.0 | ​ | ​ — | ​ | ​ — | ​ | ​ 9.0 |
| Intercompany interest income | ​ | ​ (3.2) | ​ | ​ — | ​ | ​ 3.2 | ​ | ​ — |
| Investment expense (income) | ​ | ​ (0.5) | ​ | ​ (2.7) | ​ | ​ — | ​ | ​ (3.2) |
| Total other expense (income), net | ​ | ​ 134.6 | ​ | ​ (41.0) | ​ | ​ — | ​ | ​ 93.6 |
| Earnings (loss) before income taxes | ​ | ​ (81.3) | ​ | ​ 59.5 | ​ | ​ — | ​ | ​ (21.8) |
| Income tax provision (benefit) (3) | ​ | ​ (1.1) | ​ | ​ — | ​ | ​ — | ​ | ​ (1.1) |
| Net earnings (loss) | ​ | $(80.2) | ​ | $59.5 | ​ | $— | ​ | $(20.7) |

*(unaudited)*

*(unaudited)*

*(unaudited)*

| ​ ​ ​ ​ ​ ​ ​ | ​ ​ ​ ​ ​ ​ ​ | ​ ​ Three Months Ended September 30, 2024 AMCEH & Restricted Subsidiaries/AMC Group (1) | ​ ​ ​ ​ ​ ​ | ​ ​ ​ ​ Muvico Group Unrestricted Subsidiaries (2) | ​ ​ ​ ​ ​ ​ | ​ ​ ​ ​ ​ ​ ​ Consolidated |
| --- | --- | --- | --- | --- | --- | --- |
| Net earnings (loss) | ​ | $(80.2) | ​ | $59.5 | ​ | $(20.7) |
| Other comprehensive income (loss): | ​ | ​ ​ | ​ | ​ ​ | ​ | ​ ​ |
| Unrealized foreign currency translation adjustments | ​ | ​ 8.7 | ​ | ​ — | ​ | ​ 8.7 |
| Pension adjustments: | ​ | ​ ​ | ​ | ​ ​ | ​ | ​ ​ |
| Net gain arising during the period | ​ | ​ (0.1) | ​ | ​ — | ​ | ​ (0.1) |
| Other comprehensive income | ​ | ​ 8.6 | ​ | ​ — | ​ | ​ 8.6 |
| Total comprehensive income (loss) | ​ | $(71.6) | ​ | $59.5 | ​ | $(12.1) |

(1) This column provides the information required to be presented for (i) Holdings and its Restricted Subsidiaries under the indentures governing the Exchangeable Notes and Existing First Lien Notes and (ii) AMC Group under the New Term Loan Credit Agreement. Transactions between Holdings and its restricted subsidiaries have been eliminated.

(2) The amounts presented for Muvico are from its inception on July 22, 2024 through the end of the reporting period.

(3) Muvico is a disregarded entity for federal and state income tax purposes with all tax expense and deferred taxes recorded at the Holdings level.

(4) Includes intercompany management fee revenues of $4.2 million recorded by AMCEH & Restricted Subsidiaries/AMC Group and intercompany license fee revenues of $3.9 million recorded by Muvico Group Unrestricted Subsidiaries. Corresponding amounts of expense are included in General and Administrative: Other for Muvico Group Unrestricted Subsidiaries and AMCEH & Restricted Subsidiaries/AMC Group, respectively. The amounts presented are from Muvico inception on July 22, 2024 through the end of the reporting period.

*(unaudited)*

*(unaudited)*

*(unaudited)*

| ​ ​ ​ ​ ​ ​ Key operating metrics: | ​ ​ ​ ​ ​ ​ ​ | ​ ​ Three Months Ended September 30, 2024 AMCEH & Restricted Subsidiaries/AMC Group (3) | ​ ​ ​ ​ ​ ​ | ​ ​ ​ ​ Muvico Group Unrestricted Subsidiaries (4) | ​ ​ ​ ​ ​ ​ | ​ ​ ​ ​ ​ ​ ​ Consolidated |
| --- | --- | --- | --- | --- | --- | --- |
| Average ticket price |  | $11.02 | ​ | $13.16 | ​ | $11.43 |
| Attendance (in thousands) (1) |  | ​ 52,407 | ​ | ​ 12,680 | ​ | ​ 65,087 |
| Number of screens operated (2) | ​ | ​ 7,564 | ​ | ​ 2,236 | ​ | ​ 9,800 |
| Number of theatres operated (2) | ​ | ​ 701 | ​ | ​ 173 | ​ | ​ 874 |
| Adjusted EBITDA (5) |  | $128.0 | ​ | $33.8 | ​ | $161.8 |

(1) Includes consolidated theatres only and excludes screens offline due to construction.

(2) The screens and theatres of the Muvico Group are operated by Multi-Cinema pursuant to the management agreement.

(3) This column provides the information required to be presented for (i) Holdings and its Restricted Subsidiaries under the indentures governing the Exchangeable Notes and Existing First Lien Notes and (ii) AMC Group under the New Term Loan Credit Agreement.

(4) The amounts presented for Muvico are from its inception on July 22, 2024 through the end of the reporting period.

(5) Below is a reconciliation of net loss to Adjusted EBITDA for AMCEH & Restricted Subsidiaries/AMC Group and Muvico Group. The reconciling items below have the same definitions and are of the same nature as of the reconciling items presented previously in Management’s Discussion and Analysis section of this Form 10-Q.

*(unaudited)*

*(unaudited)*

*(unaudited)*

*(unaudited)*

| Below is a reconciliation of net loss to Adjusted EBITDA for AMCEH & Restricted Subsidiaries/AMC Group and Muvico Group. The reconciling items below have the same definitions and are of the same nature as of the reconciling items presented previously in Management’s Discussion and Analysis section of this Form 10-Q. ​ ​ ​ ​ ​ ​ | ​ ​ ​ ​ ​ ​ ​ | ​ ​ Three Months Ended September 30, 2024 AMCEH & Restricted Subsidiaries/AMC Group (1) | ​ ​ ​ ​ ​ ​ | ​ ​ ​ ​ Muvico Group Unrestricted Subsidiaries (2) | ​ ​ ​ ​ ​ ​ | ​ ​ ​ ​ ​ ​ ​ ​ Eliminations | ​ ​ ​ ​ ​ ​ | ​ ​ ​ ​ ​ ​ ​ Consolidated |
| --- | --- | ---: | --- | ---: | --- | --- | --- | ---: |
| Net earnings (loss) | ​ | $(80.2) | ​ | $59.5 | ​ | $— | ​ | $(20.7) |
| Plus: | ​ | ​ ​ | ​ | ​ ​ | ​ | ​ ​ | ​ | ​ ​ |
| Income tax benefit | ​ | (1.1) | ​ | — | ​ | ​ — | ​ | (1.1) |
| Interest expense | ​ | 87.6 | ​ | 35.2 | ​ | ​ (3.2) | ​ | 119.6 |
| Depreciation and amortization | ​ | 65.7 | ​ | 15.1 | ​ | ​ — | ​ | 80.8 |
| Certain operating expense | ​ | 1.8 | ​ | 0.2 | ​ | ​ — | ​ | 2.0 |
| Equity in earnings of non-consolidated entities | ​ | (5.2) | ​ | — | ​ | ​ — | ​ | (5.2) |
| Attributable EBITDA | ​ | ​ 1.3 | ​ | ​ — | ​ | ​ — | ​ | ​ 1.3 |
| Investment income | ​ | (3.7) | ​ | (2.7) | ​ | ​ 3.2 | ​ | (3.2) |
| Other expense (income) | ​ | 55.4 | ​ | (73.5) | ​ | ​ — | ​ | (18.1) |
| General and administrative — unallocated: | ​ | ​ ​ | ​ | ​ ​ | ​ | ​ ​ | ​ | ​ ​ |
| Merger, acquisition and other costs | ​ | 0.1 | ​ | — | ​ | ​ — | ​ | 0.1 |
| Stock-based compensation expense | ​ | 6.3 | ​ | — | ​ | ​ — | ​ | 6.3 |
| Adjusted EBITDA | ​ | $128.0 | ​ | $33.8 | ​ | $— | ​ | $161.8 |

(1) This column provides the information required to be presented for (i) Holdings and its Restricted Subsidiaries under the indentures governing the Exchangeable Notes and Existing First Lien Notes and (ii) AMC Group under the New Term Loan Credit Agreement.

(2) The amounts presented for Muvico are from its inception on July 22, 2024 through the end of the reporting period.

*(In millions)*

*(unaudited)*

*(unaudited)*

*(unaudited)*

*(unaudited)*

| ​ ​ ​ ​ ​ ​ Revenues | ​ ​ ​ ​ ​ ​ ​ | ​ ​ Nine Months Ended September 30, 2024 AMCEH & Restricted Subsidiaries/AMC Group (1) ​ ​ | ​ ​ ​ ​ ​ ​ ​ | ​ ​ ​ ​ Muvico Group Unrestricted Subsidiaries (2) ​ ​ | ​ ​ ​ ​ ​ ​ ​ | ​ ​ ​ ​ ​ ​ Eliminations ​ ​ | ​ ​ ​ ​ ​ ​ ​ | ​ ​ ​ ​ ​ ​ ​ Consolidated ​ ​ |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Admissions | ​ | $1,672.2 | ​ | ​ 166.9 | ​ | ​ — | ​ | ​ 1,839.1 |
| Food and beverage | ​ | ​ 1,088.6 | ​ | ​ 90.1 | ​ | ​ — | ​ | ​ 1,178.7 |
| Other theatre (4) | ​ | ​ 300.7 | ​ | ​ 20.4 | ​ | ​ (8.1) | ​ | ​ 313.0 |
| Total revenues | ​ | ​ 3,061.5 | ​ | ​ 277.4 | ​ | ​ (8.1) | ​ | ​ 3,330.8 |
| Operating costs and expenses | ​ | ​ ​ | ​ | ​ ​ | ​ | ​ ​ | ​ | ​ ​ |
| Film exhibition costs | ​ | ​ 803.4 | ​ | ​ 89.6 | ​ | ​ — | ​ | ​ 893.0 |
| Food and beverage costs | ​ | ​ 207.5 | ​ | ​ 15.1 | ​ | ​ — | ​ | ​ 222.6 |
| Operating expense, excluding depreciation and amortization below | ​ | ​ 1,145.7 | ​ | ​ 92.2 | ​ | ​ — | ​ | ​ 1,237.9 |
| Rent | ​ | ​ 616.6 | ​ | ​ 42.7 | ​ | ​ — | ​ | ​ 659.3 |
| General and administrative: | ​ | ​ ​ | ​ | ​ ​ | ​ | ​ ​ | ​ | ​ ​ |
| Merger, acquisition and other costs | ​ | ​ 0.1 | ​ | ​ — | ​ | ​ — | ​ | ​ 0.1 |
| Other, excluding depreciation and amortization below (4) | ​ | ​ 164.6 | ​ | ​ 4.2 | ​ | ​ (8.1) | ​ | ​ 160.7 |
| Depreciation and amortization | ​ | ​ 226.1 | ​ | ​ 15.1 | ​ | ​ — | ​ | ​ 241.2 |
| Operating costs and expenses | ​ | ​ 3,164.0 | ​ | ​ 258.9 | ​ | ​ (8.1) | ​ | ​ 3,414.8 |
| Operating income (loss) | ​ | ​ (102.5) | ​ | ​ 18.5 | ​ | ​ — | ​ | ​ (84.0) |
| Other expense, net: | ​ | ​ ​ | ​ | ​ ​ | ​ | ​ ​ | ​ | ​ ​ |
| Other income, net | ​ | ​ (100.3) | ​ | ​ (73.5) | ​ | ​ — | ​ | ​ (173.8) |
| Interest expense: | ​ | ​ ​ | ​ | ​ ​ | ​ | ​ ​ | ​ | ​ ​ |
| Corporate borrowings | ​ | ​ 257.8 | ​ | ​ 32.0 | ​ | ​ — | ​ | ​ 289.8 |
| Finance lease obligations | ​ | ​ 2.5 | ​ | ​ — | ​ | ​ — | ​ | ​ 2.5 |
| Intercompany interest expense | ​ | ​ 1.8 | ​ | ​ 3.2 | ​ | ​ (5.0) | ​ | ​ — |
| Non-cash NCM exhibitor services agreement | ​ | ​ 27.5 | ​ | ​ — | ​ | ​ — | ​ | ​ 27.5 |
| Intercompany interest income | ​ | ​ (3.2) | ​ | ​ (1.8) | ​ | ​ 5.0 | ​ | ​ — |
| Investment expense (income) | ​ | ​ (11.7) | ​ | ​ (2.7) | ​ | ​ — | ​ | ​ (14.4) |
| Total other expense (income), net | ​ | ​ 174.4 | ​ | ​ (42.8) | ​ | ​ — | ​ | ​ 131.6 |
| Earnings (loss) before income taxes | ​ | ​ (276.9) | ​ | ​ 61.3 | ​ | ​ — | ​ | ​ (215.6) |
| Income tax provision (benefit) (3) | ​ | ​ 1.4 | ​ | ​ — | ​ | ​ — | ​ | ​ 1.4 |
| Net earnings (loss) | ​ | $(278.3) | ​ | $61.3 | ​ | $— | ​ | $(217.0) |

*(unaudited)*

*(unaudited)*

*(unaudited)*

| ​ ​ ​ ​ ​ ​ ​ | ​ ​ ​ ​ ​ ​ ​ | ​ ​ Nine Months Ended September 30, 2024 AMCEH & Restricted Subsidiaries/AMC Group (1) | ​ ​ ​ ​ ​ ​ | ​ ​ ​ ​ Muvico Group Unrestricted Subsidiaries (2) | ​ ​ ​ ​ ​ ​ | ​ ​ ​ ​ ​ ​ ​ Consolidated |
| --- | --- | --- | --- | --- | --- | --- |
| Net earnings (loss) | ​ | $(278.3) | ​ | $61.3 | ​ | $(217.0) |
| Other comprehensive income (loss): | ​ | ​ ​ | ​ | ​ ​ | ​ | ​ ​ |
| Unrealized foreign currency translation adjustments | ​ | ​ (24.4) | ​ | ​ — | ​ | ​ (24.4) |
| Pension adjustments: | ​ | ​ ​ | ​ | ​ ​ | ​ | ​ ​ |
| Net loss arising during the period | ​ | ​ 0.4 | ​ | ​ — | ​ | ​ 0.4 |
| Other comprehensive loss | ​ | ​ (24.0) | ​ | ​ — | ​ | ​ (24.0) |
| Total comprehensive income (loss) | ​ | $(302.3) | ​ | $61.3 | ​ | $(241.0) |

(1) This column provides the information required to be presented for (i) Holdings and its Restricted Subsidiaries under the indentures governing the Exchangeable Notes and Existing First Lien Notes and (ii) AMC Group under the New Term Loan Credit Agreement.

(2) The amounts presented for Muvico are from its inception on July 22, 2024 through the end of the reporting period.

(3) Muvico is a disregarded entity for federal and state income tax purposes with all tax expense and deferred taxes recorded at the Holdings level.

(4) Includes intercompany management fee revenues of $4.2 million recorded by AMCEH & Restricted Subsidiaries/AMC Group and intercompany license fee revenues of $3.9 million recorded by Muvico Group Unrestricted Subsidiaries. Corresponding amounts of expense are included in General and Administrative: Other for Muvico Group Unrestricted Subsidiaries and AMCEH & Restricted Subsidiaries/AMC Group, respectively. The amounts presented are from Muvico inception on July 22, 2024 through the end of the reporting period.

*(unaudited)*

*(unaudited)*

*(unaudited)*

| ​ ​ ​ ​ ​ ​ Key operating metrics: | ​ ​ ​ ​ ​ ​ ​ | ​ ​ Nine Months Ended September 30, 2024 AMCEH & Restricted Subsidiaries/AMC Group (3) | ​ ​ ​ ​ ​ ​ | ​ ​ ​ ​ Muvico Group Unrestricted Subsidiaries (4) | ​ ​ ​ ​ ​ ​ | ​ ​ ​ ​ ​ ​ ​ Consolidated |
| --- | --- | --- | --- | --- | --- | --- |
| Average ticket price |  | $11.22 | ​ | $13.16 | ​ | $11.37 |
| Attendance (in thousands) (1) | ​ | ​ 149,051 | ​ | ​ 12,680 | ​ | ​ 161,731 |
| Number of screens operated (2) |  | ​ 7,564 | ​ | ​ 2,236 | ​ | ​ 9,800 |
| Number of theatres operated (2) |  | ​ 701 | ​ | ​ 173 | ​ | ​ 874 |
| Adjusted EBITDA (5) |  | $145.3 | ​ | $33.8 | ​ | $179.1 |

(1) Includes consolidated theatres only and excludes screens offline due to construction.

(2) The screens and theatres of the Muvico Group are operated by Multi-Cinema pursuant to the management agreement.

(3) This column provides the information required to be presented for (i) Holdings and its Restricted Subsidiaries under the indentures governing the Exchangeable Notes and Existing First Lien Notes and (ii) AMC Group under the New Term Loan Credit Agreement.

(4) The amounts presented for Muvico are from its inception on July 22, 2024 through the end of the reporting period.

(5) Below is a reconciliation of net loss to Adjusted EBITDA for AMCEH & Restricted Subsidiaries/AMC Group and Muvico Group. The reconciling items below have the same definitions and are of the same nature as of the reconciling items presented previously in Management’s Discussion and Analysis section of this Form 10-Q.

*(unaudited)*

*(unaudited)*

*(unaudited)*

*(unaudited)*

| ​ ​ ​ ​ ​ ​ ​ | ​ ​ ​ ​ ​ ​ ​ | ​ ​ Nine Months Ended September 30, 2024 AMCEH & Restricted Subsidiaries/AMC Group (1) | ​ ​ ​ ​ ​ ​ | ​ ​ ​ ​ Muvico Group Unrestricted Subsidiaries (2) | ​ ​ ​ ​ ​ ​ | ​ ​ ​ ​ ​ ​ ​ ​ Eliminations | ​ ​ ​ ​ ​ ​ | ​ ​ ​ ​ ​ ​ ​ Consolidated |
| --- | --- | ---: | --- | ---: | --- | --- | --- | ---: |
| Net earnings (loss) | ​ | $(278.3) | ​ | $61.3 | ​ | $— | ​ | $(217.0) |
| Plus: | ​ | ​ ​ | ​ | ​ ​ | ​ | ​ ​ | ​ | ​ ​ |
| Income tax provision | ​ | 1.4 | ​ | — | ​ | ​ — | ​ | 1.4 |
| Interest expense | ​ | 289.6 | ​ | 35.2 | ​ | ​ (5.0) | ​ | 319.8 |
| Depreciation and amortization | ​ | 226.1 | ​ | 15.1 | ​ | ​ — | ​ | 241.2 |
| Certain operating expense | ​ | 3.3 | ​ | 0.2 | ​ | ​ — | ​ | 3.5 |
| Equity in earnings of non-consolidated entities | ​ | (9.9) | ​ | — | ​ | ​ — | ​ | (9.9) |
| Attributable EBITDA | ​ | ​ 1.2 | ​ | ​ — | ​ | ​ — | ​ | ​ 1.2 |
| Investment income | ​ | (14.9) | ​ | (4.5) | ​ | ​ 5.0 | ​ | (14.4) |
| Other income, net | ​ | (88.4) | ​ | (73.5) | ​ | ​ — | ​ | (161.9) |
| General and administrative — unallocated: | ​ | ​ ​ | ​ | ​ ​ | ​ | ​ ​ | ​ | ​ ​ |
| Merger, acquisition and other costs | ​ | 0.1 | ​ | — | ​ | ​ — | ​ | 0.1 |
| Stock-based compensation expense | ​ | 15.1 | ​ | — | ​ | ​ — | ​ | 15.1 |
| Adjusted EBITDA | ​ | $145.3 | ​ | $33.8 | ​ | $— | ​ | $179.1 |

(1) This column provides the information required to be presented for (i) Holdings and its Restricted Subsidiaries under the indentures governing the Exchangeable Notes and Existing First Lien Notes and (ii) AMC Group under the New Term Loan Credit Agreement.

(2) The amounts presented for Muvico are from its inception on July 22, 2024 through the end of the reporting period.

*(In millions, except share data)*

*(unaudited)*

*(unaudited)*

*(unaudited)*

*(unaudited)*

| ​ ​ ​ ​ ​ ​ ASSETS Current assets: | ​ ​ ​ ​ ​ ​ ​ ​ ​ | ​ ​ As of September 30, 2024 AMCEH & Restricted Subsidiaries/AMC Group (3) ​ ​ ​ ​ | ​ ​ ​ ​ ​ ​ ​ ​ | ​ ​ ​ ​ Muvico Group Unrestricted Subsidiaries ​ ​ ​ ​ | ​ ​ ​ ​ ​ ​ ​ ​ | ​ ​ ​ ​ ​ ​ Eliminations ​ ​ ​ ​ | ​ ​ ​ ​ ​ ​ ​ ​ | ​ ​ ​ ​ ​ ​ ​ Consolidated ​ ​ ​ ​ |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Cash and cash equivalents (1) | ​ | $197.7 | ​ | $329.7 | ​ | $— | ​ | $527.4 |
| Restricted cash | ​ | ​ 49.7 | ​ | ​ — | ​ | ​ — | ​ | ​ 49.7 |
| Receivables, net | ​ | ​ 104.4 | ​ | ​ 3.7 | ​ | ​ — | ​ | ​ 108.1 |
| Other current assets | ​ | ​ 66.0 | ​ | ​ 37.9 | ​ | ​ — | ​ | ​ 103.9 |
| Total current assets | ​ | ​ 417.8 | ​ | ​ 371.3 | ​ | ​ — | ​ | ​ 789.1 |
| Property, net | ​ | ​ 1,105.8 | ​ | ​ 378.6 | ​ | ​ — | ​ | ​ 1,484.4 |
| Operating lease right-of-use assets, net | ​ | ​ 2,539.2 | ​ | ​ 812.7 | ​ | ​ — | ​ | ​ 3,351.9 |
| Intangible assets, net | ​ | ​ 42.8 | ​ | ​ 104.4 | ​ | ​ — | ​ | ​ 147.2 |
| Goodwill | ​ | ​ 2,351.6 | ​ | ​ — | ​ | ​ — | ​ | ​ 2,351.6 |
| Deferred tax asset, net (4) | ​ | ​ 0.5 | ​ | ​ — | ​ | ​ — | ​ | ​ 0.5 |
| Other long-term assets | ​ | ​ 198.7 | ​ | ​ 0.7 | ​ | ​ — | ​ | ​ 199.4 |
| Intercompany receivables (2) | ​ | ​ — | ​ | ​ 1,373.6 | ​ | ​ (1,373.6) | ​ | ​ — |
| Investment in subsidiary | ​ | ​ 635.5 | ​ | ​ — | ​ | ​ (635.5) | ​ | ​ — |
| Total assets | ​ | $7,291.9 | ​ | $3,041.3 | ​ | $(2,009.1) | ​ | $8,324.1 |
| **LIABILITIES AND STOCKHOLDERS’ DEFICIT** | ​ | ​ ​ | ​ | ​ ​ | ​ | ​ ​ | ​ | ​ ​ |
| Current liabilities: | ​ | ​ ​ | ​ | ​ ​ | ​ | ​ ​ | ​ | ​ ​ |
| Accounts payable | ​ | $221.7 | ​ | $26.0 | ​ | $— | ​ | $247.7 |
| Accrued expenses and other liabilities | ​ | ​ 284.6 | ​ | ​ 33.7 | ​ | ​ — | ​ | ​ 318.3 |
| Deferred revenues and income | ​ | ​ 382.3 | ​ | ​ 2.8 | ​ | ​ — | ​ | ​ 385.1 |
| Current maturities of corporate borrowings | ​ | ​ 85.5 | ​ | ​ 10.1 | ​ | ​ — | ​ | ​ 95.6 |
| Current maturities of finance lease liabilities | ​ | ​ 4.6 | ​ | ​ — | ​ | ​ — | ​ | ​ 4.6 |
| Current maturities of operating lease liabilities | ​ | ​ 384.8 | ​ | ​ 142.8 | ​ | ​ — | ​ | ​ 527.6 |
| Total current liabilities | ​ | ​ 1,363.5 | ​ | ​ 215.4 | ​ | ​ — | ​ | ​ 1,578.9 |
| Corporate borrowings | ​ | ​ 2,640.3 | ​ | ​ 1,408.1 | ​ | ​ — | ​ | ​ 4,048.4 |
| Finance lease liabilities | ​ | ​ 48.6 | ​ | ​ — | ​ | ​ — | ​ | ​ 48.6 |
| Operating lease liabilities | ​ | ​ 2,959.4 | ​ | ​ 778.9 | ​ | ​ — | ​ | ​ 3,738.3 |
| Exhibitor services agreement | ​ | ​ 469.8 | ​ | ​ — | ​ | ​ — | ​ | ​ 469.8 |
| Deferred tax liability, net (4) | ​ | ​ 34.0 | ​ | ​ — | ​ | ​ — | ​ | ​ 34.0 |
| Intercompany payables (2) | ​ | ​ 1,373.6 | ​ | ​ — | ​ | ​ (1,373.6) | ​ | ​ — |
| Other long-term liabilities | ​ | ​ 88.0 | ​ | ​ 3.4 | ​ | ​ — | ​ | ​ 91.4 |
| Total liabilities | ​ | ​ 8,977.2 | ​ | ​ 2,405.8 | ​ | ​ (1,373.6) | ​ | ​ 10,009.4 |
| Commitments and contingencies | ​ | ​ ​ | ​ | ​ ​ | ​ | ​ ​ | ​ | ​ ​ |
| Stockholders’ deficit: | ​ | ​ ​ | ​ | ​ ​ | ​ | ​ ​ | ​ | ​ ​ |
| AMC Entertainment Holdings, Inc.'s stockholders' deficit: | ​ | ​ ​ | ​ | ​ ​ | ​ | ​ ​ | ​ | ​ ​ |
| Preferred stock | ​ | ​ — | ​ | ​ — | ​ | ​ — | ​ | ​ — |
| Class A common stock | ​ | ​ 3.6 | ​ | ​ — | ​ | ​ — | ​ | ​ 3.6 |
| Additional paid-in capital | ​ | ​ 6,624.5 | ​ | ​ 558.3 | ​ | ​ (558.3) | ​ | ​ 6,624.5 |
| Accumulated other comprehensive loss | ​ | ​ (102.2) | ​ | ​ — | ​ | ​ — | ​ | ​ (102.2) |
| Accumulated deficit | ​ | ​ (8,211.2) | ​ | ​ 77.2 | ​ | ​ (77.2) | ​ | ​ (8,211.2) |
| Total stockholders' deficit | ​ | ​ (1,685.3) | ​ | ​ 635.5 | ​ | ​ (635.5) | ​ | ​ (1,685.3) |
| Total liabilities and stockholders’ deficit | ​ | $7,291.9 | ​ | $3,041.3 | ​ | $(2,009.1) | ​ | $8,324.1 |

(1) The cash held in bank accounts differs from the book balance due to deposits in transit, payments in transit, and certain cash equivalents.

(2) Intercompany receivables (payables) includes intercompany loans, fees receivable/payable pursuant to the management agreement and intellectual property license agreement, the intercompany receivable/payable created by allocating the New Term Loans borrowings between Holdings and Muvico, and other intercompany balances created due to the Refinancing Transactions.

(3) This column provides the information required to be presented for (i) Holdings and its Restricted Subsidiaries under the indentures governing the Exchangeable Notes and Existing First Lien Notes and (ii) AMC Group under the New Term Loan Credit Agreement.

(4) Muvico is a disregarded entity for federal and state income tax purposes with all tax expense and deferred taxes recorded at the Holdings level.

*(unaudited)*

*(unaudited)*

*(unaudited)*

| ​ ​ ​ ​ ​ ​ ​ | ​ ​ ​ ​ ​ ​ ​ | ​ ​ Nine Months Ended September 30, 2024 AMCEH & Restricted Subsidiaries/AMC Group (1) | ​ ​ ​ ​ ​ ​ | ​ ​ ​ ​ Muvico Group Unrestricted Subsidiaries (2) | ​ ​ ​ ​ ​ ​ | ​ ​ ​ ​ ​ ​ ​ Consolidated |
| --- | --- | --- | --- | --- | --- | --- |
| Net (loss) earnings | ​ | $(278.3) | ​ | $61.3 | ​ | $(217.0) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ​ | ​ ​ | ​ | ​ ​ | ​ | ​ ​ |
| Depreciation and amortization | ​ | ​ 226.1 | ​ | ​ 15.1 | ​ | ​ 241.2 |
| (Gain) loss on extinguishment of debt | ​ | ​ (40.3) | ​ | ​ — | ​ | ​ (40.3) |
| Gain on derivative liability | ​ | ​ — | ​ | ​ (73.5) | ​ | ​ (73.5) |
| Deferred income taxes | ​ | ​ 1.1 | ​ | ​ — | ​ | ​ 1.1 |
| Unrealized loss on investments in Hycroft | ​ | ​ 1.7 | ​ | ​ — | ​ | ​ 1.7 |
| Amortization of (premium) discount on corporate borrowings to interest expense | ​ | ​ (23.8) | ​ | ​ 3.7 | ​ | ​ (20.1) |
| Amortization of deferred financing costs to interest expense | ​ | ​ 6.1 | ​ | ​ 0.6 | ​ | ​ 6.7 |
| Non-cash portion of stock-based compensation | ​ | ​ 15.1 | ​ | ​ — | ​ | ​ 15.1 |
| Equity in loss (earnings) from non-consolidated entities, net of distributions | ​ | ​ (3.3) | ​ | ​ — | ​ | ​ (3.3) |
| Landlord contributions | ​ | ​ 26.0 | ​ | ​ — | ​ | ​ 26.0 |
| Deferred rent | ​ | ​ (78.9) | ​ | ​ (3.2) | ​ | ​ (82.1) |
| Net periodic benefit cost | ​ | ​ 1.5 | ​ | ​ — | ​ | ​ 1.5 |
| Change in assets and liabilities: | ​ | ​ ​ | ​ | ​ ​ | ​ | ​ ​ |
| Receivables | ​ | ​ 91.7 | ​ | ​ 6.9 | ​ | ​ 98.6 |
| Other assets | ​ | ​ 2.1 | ​ | ​ (14.9) | ​ | ​ (12.8) |
| Accounts payable | ​ | ​ (50.7) | ​ | ​ (31.9) | ​ | ​ (82.6) |
| Accrued expenses and other liabilities | ​ | ​ (91.1) | ​ | ​ 0.1 | ​ | ​ (91.0) |
| Intercompany receivables and payables | ​ | ​ (130.2) | ​ | ​ 130.2 | ​ | ​ — |
| Other, net | ​ | ​ (23.6) | ​ | ​ — | ​ | ​ (23.6) |
| Net cash (used in) provided by operating activities | ​ | ​ (348.8) | ​ | ​ 94.4 | ​ | ​ (254.4) |
| **Cash flows from investing activities:** | **​** | ​ ​ | ​ | ​ ​ | ​ | ​ ​ |
| Capital expenditures | ​ | ​ (146.9) | ​ | ​ (8.9) | ​ | ​ (155.8) |
| Proceeds from disposition of long-term assets | ​ | ​ 0.3 | ​ | ​ — | ​ | ​ 0.3 |
| Cash contributed to Muvico Group | ​ | ​ (3.9) | ​ | ​ 3.9 | ​ | ​ — |
| Other, net | ​ | ​ 1.5 | ​ | ​ — | ​ | ​ 1.5 |
| Net cash used in investing activities | ​ | ​ (149.0) | ​ | ​ (5.0) | ​ | ​ (154.0) |
| **Cash flows from financing activities:** | **​** | ​ ​ | ​ | ​ ​ | ​ | ​ ​ |
| Repurchase of Senior Subordinated Notes due 2025 | **​** | ​ (12.9) | ​ | ​ — | ​ | ​ (12.9) |
| Repurchase of Senior Subordinated Notes due 2026 | ​ | ​ (6.0) | ​ | ​ — | ​ | ​ (6.0) |
| Repurchase of Second Lien Notes due 2026 | ​ | ​ (83.2) | ​ | ​ — | ​ | ​ (83.2) |
| Scheduled principal payments under Term Loan borrowings | ​ | ​ (12.6) | ​ | ​ (2.5) | ​ | ​ (15.1) |
| Principal payments under Term Loan due 2026 | ​ | ​ (27.0) | ​ | ​ — | ​ | ​ (27.0) |
| Proceeds from issuance of Term Loan due 2029 | ​ | ​ 27.0 | ​ | ​ — | ​ | ​ 27.0 |
| Net proceeds from equity issuances | ​ | ​ 243.0 | ​ | ​ — | ​ | ​ 243.0 |
| Principal payments under finance lease obligations | ​ | ​ (3.5) | ​ | ​ — | ​ | ​ (3.5) |
| Cash used to pay for deferred financing costs | ​ | ​ (11.0) | ​ | ​ (34.7) | ​ | ​ (45.7) |
| Debt extinguishment costs | ​ | ​ (2.3) | ​ | ​ — | ​ | ​ (2.3) |
| Taxes paid for restricted unit withholdings | ​ | ​ (2.2) | ​ | ​ — | ​ | ​ (2.2) |
| Proceeds (payments) of intercompany loans | ​ | ​ (266.2) | ​ | ​ 266.2 | ​ | ​ — |
| Net cash provided by (used in) financing activities | ​ | ​ (156.9) | ​ | ​ 229.0 | ​ | ​ 72.1 |
| Effect of exchange rate changes on cash and cash equivalents and restricted cash | ​ | ​ 2.0 | ​ | ​ — | ​ | ​ 2.0 |

72

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| **Net increase (decrease) in cash and cash equivalents and restricted cash** | **​** | ​ (652.7) | ​ | ​ 318.4 | ​ | ​ (334.3) |
| **Cash and cash equivalents and restricted cash at beginning of period** | **​** | ​ 900.1 | ​ | ​ 11.3 | ​ | ​ 911.4 |
| **Cash and cash equivalents and restricted cash at end of period** | **​** | $247.4 | ​ | $329.7 | ​ | $577.1 |

(1) This column provides the information required to be presented for (i) Holdings and its Restricted Subsidiaries under the indentures governing the Exchangeable Notes and Existing First Lien Notes and (ii) AMC Group under the New Term Loan Credit Agreement.

(2) The amounts presented for Muvico are from its inception on July 22, 2024 through the end of the reporting period.

## Market risk

As filed, 7,320 characters.

In the ordinary course of business, our financial results are exposed to fluctuations in interest rates and foreign currency exchange rates. In accordance with applicable guidance, we presented a sensitivity analysis showing the potential impact to net income of changes in interest rates and foreign currency exchange rates. For the nine months ended September 30, 2024 and September 30, 2023, our analysis utilized a hypothetical 100 basis-point increase or decrease to the average interest rate on our variable rate debt instruments to illustrate the potential impact to interest expense of changes in interest rates and a hypothetical 100 basis-point increase or decrease to market interest rates on our fixed rate debt instruments to illustrate the potential impact to fair value of changes in interest rates.

Similarly, for the same period, our analysis used a uniform and hypothetical 10% increase in foreign currency translation rates to depict the potential impact to net income of changes in foreign exchange rates. These market risk instruments and the potential impacts to the condensed consolidated statements of operations are presented below.

**Market risk on variable-rate financial instruments.** As of September 30, 2024, we had an aggregate of $2,019.3 million outstanding principal amount of our New Term Loans which bear interest, at our option, at rates equal to either (i) a base rate plus a margin of between 500 and 600 basis points depending on the total leverage ratio of the Company and its subsidiaries on a consolidated basis (the “Total Leverage Ratio”) or (ii) Term SOFR plus a margin of between 600 and 700 basis points depending on the Total Leverage Ratio. Until the delivery under the New Term Loan Credit Agreement of the financial statements for the first full fiscal quarter ending after the Closing Date, the New Term Loans bear interest, at the option of the Company, at either (a) the base rate plus a margin of 600 basis points or (b) Term SOFR plus a margin of 700 basis points.

Prior to the Refinancing Transactions we had outstanding Existing Term Loans under the Credit Agreement dated April 30, 2013 (as amended, restated, amended and restated, supplemented or otherwise modified) which bore interest at a rate per annum equal to, at our option, either (1) a base rate determined by reference to the highest of (a) 0.50% per annum plus the Federal Funds Effective Rate, (b) the prime rate announced by the administrative agent and (c) 1.00% per annum plus Adjusted Term SOFR (as defined below) for a 1-month tenor or (2) Term SOFR plus a credit spread adjustment of 0.11448% per annum, 0.26161% per annum, and 0.42826% per annum for interest periods of one-month, three-months, or six-months or longer, respectively (“Adjusted Term SOFR”) plus in the case of the Existing Term Loans, 2.0% for base rate loans or 3.0% for SOFR loans.

The rate in effect for the outstanding New Term Loans was 11.919% per annum at September 30, 2024, and 8.427% per annum for the Existing Term Loans at September 30, 2023.

Increases in market interest rates would cause interest expense to increase and earnings before income taxes to decrease. The change in interest expense and earnings before income taxes would be dependent upon the weighted average outstanding borrowings during the reporting period following an increase in market interest rates. A 100-basis point change in market interest rates would have increased or decreased interest expense on the Existing Term Loans and New Term Loans by approximately $14.5 million during the nine months ended September 30, 2024.

At September 30, 2023, we had an aggregate principal balance of $1,910.0 million outstanding under the Existing Term Loans. A 100-basis point change in market interest rates would have increased or decreased interest expense on our Existing Term Loans by $14.3 million during the nine months ended September 30, 2023.

**Market risk on fixed-rate financial instruments.** Included in corporate borrowings as of September 30,

2024, were principal amounts of $414.4 million of our Exchangeable Notes, $950.0 million of our Existing First Lien Notes, $163.9 million of our Second Lien Notes, $400.0 million of our 12.75% Odeon Senior Secured Notes due 2027 (“Odeon Notes due 2027”), $82.7 million of our 5.75% Senior Subordinated Notes due 2025 (“Notes due 2025”), $41.9 million of our 5.875% Senior Subordinated Notes due 2026 (“Notes due 2026”), $125.5 million of our 6.125% Senior Subordinated Notes due 2027 (“Notes due 2027”), and £4.0 million ($5.3 million) of our 6.375% Senior Subordinated Notes due 2024 (“Sterling Notes due 2024”). A 100-basis point change in market interest rates would have caused an increase or (decrease) in the fair value of our fixed rate financial instruments of approximately $65.4 million and $(62.6) million, respectively, as of September 30, 2024.

Included in corporate borrowings as of September 30, 2023, were principal amounts of $950.0 million of our Existing First Lien Notes, $1,124.2 million of our Second Lien Notes, $400.0 million of our Odeon Notes due 2027, $98.3 million of our Notes due 2025, $51.5 million of our Notes due 2026, $125.5 million of our Notes due 2027, and £4.0 million ($4.9 million) of our Sterling Notes due 2024. A 100-basis point change in market interest rates would have caused an increase or (decrease) in the fair value of our fixed rate financial instruments of approximately $60.1 million and $(57.7) million, respectively, as of September 30, 2023.

**Foreign currency exchange rate risk.** We are also exposed to market risk arising from changes in foreign currency exchange rates arising from our International markets operations. International markets revenues and operating expenses are transacted in British Pounds, Euros, Swedish Krona, and Norwegian Krone. U.S. GAAP requires that our subsidiaries use the currency of the primary economic environment in which they operate as their functional currency. If any international subsidiary was to operate in a highly inflationary economy, U.S. GAAP would require that the U.S. dollar be used as the functional currency. Currency fluctuations in the countries in which we operate result in us reporting exchange gains (losses) or foreign currency translation adjustments. Based upon the functional currencies in the International markets as of September 30, 2024, holding everything else constant, a hypothetical 10% increase in foreign currency translation rates to depict the potential impact to net loss of changes in foreign exchange rates would increase the aggregate net loss of our International theatres for the nine months ended September 30, 2024, by approximately $5.1 million. Based upon the functional currencies in the International markets as of September 30, 2023, holding everything else constant, a hypothetical 10% increase in foreign currency translation rates to depict the potential impact to net loss of changes in foreign exchange rates would increase the aggregate net loss of our International theatres for the nine months ended September 30, 2023, by approximately $4.4 million.

Our foreign currency translation rates increased by approximately 1.1% for the nine months ended September 30, 2024, compared to the nine months ended September 30, 2023.

## Controls and procedures

As filed, 1,169 characters.

(a) Evaluation of disclosure controls and procedures.

The Company maintains a set of disclosure controls and procedures designed to ensure that material information required to be disclosed in its filings under the Securities Exchange Act of 1934 is recorded, processed, summarized and reported within the time periods specified in the Securities and Exchange Commission’s rules and forms and that material information is accumulated and communicated to the Company’s management, including its Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure. The Company’s Chief Executive Officer and Chief Financial Officer have evaluated these disclosure controls and procedures as of the end of the period covered by this Quarterly Report on Form 10–Q and have determined that such disclosure controls and procedures were effective.

(b) Changes in internal control.

There has been no change in our internal control over financial reporting during our most recent calendar quarter that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

## Risk factors

As filed, 12,154 characters.

Reference is made to Part I Item 1A. Risk Factors in our Annual Report on Form 10–K for the year ended December 31, 2023, which sets forth information relating to important risks and uncertainties that could materially adversely affect our business, financial condition or operating results. Except as set forth below, there have been no material changes to the risk factors contained in our Annual Report on Form 10-K for the year ended December 31, 2023 and Part II Item 1A. in our Quarterly Report on Form 10-Q for the quarter ended June 30, 2024.

***There has been significant recent dilution and there may continue to be significant additional future dilution of our Common Stock, which could adversely affect the market price of shares of our Common Stock.***

From January 1, 2020 through November 5, 2024, the outstanding shares of our Common Stock have increased by 370,471,691 shares (on a Reverse Stock Split adjusted basis) in a combination of at-the-market sales, conversion of Series A Convertible Participating Preferred Stock, shareholder litigation settlement, conversion of Class B common stock, conversion of notes, exchanges of notes, transaction fee payments, and equity grant vesting. On March 14, 2023, the Company held the Special Meeting and obtained the requisite stockholder approval for the Charter Amendments (as defined in the annual report on Form 10-K for the year ended December 31, 2023) and on August 14, 2023 we filed the amendment to our Certificate of Incorporation implementing the Charter Amendments effective as of August 24, 2023. In accordance with the Charter Amendments, we increased the total number of authorized shares of Common Stock from 524,173,073 to 550,000,000 shares of Common Stock and effectuated a reverse stock split at a ratio of one share of Common Stock for every ten shares of Common Stock outstanding. In accordance with the terms of the Certificate of Designations governing the Series A Convertible Participating Preferred Stock, following the effectiveness of the Charter Amendments all outstanding shares of our Series A Convertible Participating Preferred Stock converted into 99,540,642 shares of Common Stock. On July 22, 2024, as part of the Refinancing Transactions, Muvico issued the Exchangeable Notes and the Additional Exchangeable Notes that are exchangeable into our Common Stock pursuant to the indenture governing the Exchangeable Notes.

If the Exchangeable Notes and the Additional Exchangeable Notes are converted fully into shares of our Common Stock, they will be converted into an aggregate of up to 92,584,105 shares of Common Stock, which represents the maximum number of shares of Common Stock issuable upon conversion of the Exchangeable Notes, including a make-whole fee, determined as if the Additional Notes had been purchased by the holders of the Exchangeable Notes, and the outstanding Exchangeable Notes were converted in full as of the trading day immediately preceding the date of this report, without regard to any limitations on the conversion therein.

If the Exchangeable Notes and Additional Exchangeable Notes are converted fully into shares of our Common Stock prior to maturity, without regard to any limitations on the conversion therein, the maximum number of the Additional Exchangeable Notes are issued, and Muvico elects to pay interest by issuing PIK Notes during the life of the Exchangeable Notes, they will be converted into an aggregate of up to 129,051,873 shares of Common Stock representing the maximum number of shares of Common Stock issuable upon conversion therein.

As of November 5, 2024, there were 375,679,699 shares of Common Stock issued and outstanding. We expect to issue additional shares of Common Stock to raise cash to bolster our liquidity, to repay, refinance, redeem or refinance indebtedness (including expenses, accrued interest and premium, if any), for working capital, to finance strategic initiatives and future acquisitions, to settle conversion of the Exchangeable Notes, including any PIK Notes and Additional Exchangeable Notes, or for other purposes. We may also issue preferred equity securities or securities convertible into, or exchangeable for, or that represent the right to receive, shares of Common Stock or acquire interests in other companies, or other assets by using a combination of cash and shares of Common Stock, or just shares of Common Stock. The holders of the Exchangeable Notes may from time to time convert the Exchangeable Notes and Additional Exchangeable Notes into shares of our Common Stock, and Muvico may elect to pay interest-in-kind by issuing PIK

Notes. Additionally, vesting of outstanding awards pursuant to our current and legacy equity compensation programs results in the issuance of new shares of Common Stock, net of any shares withheld to cover tax withholding obligations upon vesting. Any of these events may significantly dilute the ownership interests of current stockholders, reduce our earnings per share or have an adverse effect on the price of our shares of Common Stock.

***The market price and trading volume of our shares of Common Stock have experienced, and may continue to experience, extreme volatility, which could cause purchasers of our Common Stock to incur substantial losses.***

The market prices and trading volume of our shares of Common Stock have experienced, and may continue to experience, extreme volatility, which could cause purchasers of our Common Stock to incur substantial losses. For example, during 2023 and 2024 to date, as adjusted for the Reverse Stock Split, the market price of our Common Stock has fluctuated from an intra-day low on the New York Stock Exchange (“NYSE”) of $2.38 per share on April 16, 2024 to an intra-day high on the NYSE of $85.30 on February 28, 2023. The last reported sale price of our Common Stock on the NYSE on November 5, 2024, was $4.39 per share. During 2023 and 2024 to date, daily trading volume ranged from approximately 771,720 to 634,246,600 shares.

We believe that volatility and market prices of our shares may reflect market and trading dynamics unrelated to our underlying business, or macro or industry fundamentals, and we do not know how long these dynamics will last.

Extreme fluctuations in the market price of our Common Stock have been accompanied by reports of strong and atypical retail investor interest, including on social media and online forums. The market volatility and trading patterns we have experienced create several risks for investors, including the following:

- the market prices of our Common Stock have experienced and may continue to experience rapid and substantial increases or decreases unrelated to our operating performance or prospects, or macro or industry fundamentals, and substantial increases may be significantly inconsistent with the risks and uncertainties that we continue to face;
- factors in the public trading market for our Common Stock may include the sentiment of retail investors (including as may be expressed on financial trading and other social media sites and online forums), the direct access by retail investors to broadly available trading platforms, the amount and status of short interest in our securities, access to margin debt, trading in options and other derivatives on our Common Stock and any related hedging and other trading factors;
- our market capitalization, as implied by various trading prices, currently reflects valuations that diverge significantly from historical valuations, and to the extent these valuations reflect trading dynamics unrelated to our financial performance or prospects, purchasers of our Common Stock could incur substantial losses if there are declines in market prices;
- to the extent volatility in our Common Stock is caused, or may from time to time be caused, as has widely been reported, by a “short squeeze” in which coordinated trading activity causes a spike in the market price of our Common Stock as traders with a short position make market purchases to avoid or to mitigate potential losses, investors purchase at inflated prices unrelated to our financial performance or prospects, and may thereafter suffer substantial losses as prices decline once the level of short-covering purchases has abated; and
- if the market prices of our Common Stock declines, investors may be unable to resell shares of our Common Stock at or above the price at which their investment was made. Our Common Stock may continue to fluctuate or decline significantly in the future, which may result in substantial losses.

The market price of our Common Stock could also be negatively affected by any unfavorable outcome in the Noteholder Action described in Note 11—Commitments and Contingencies of the Notes to the Company’s Condensed Consolidated Financial Statements in Item 1 of Part I of this Form 10-Q or by any other action brought by note holders resulting from the Refinancing Transactions. If it is determined that the Company breached, as claimed, the Intercreditor Agreement, this would permit note holders to claim an event of default occurred under the indenture governing the Existing First Lien Notes and, subject to any conditions in the indenture, permit note holders to accelerate the Existing First Lien Notes, which could in turn result in the acceleration of the Company’s other outstanding debt. Such an event would thereby have a material adverse effect on our business, financial condition and results of operations and on the market prices of our securities, including our Common Stock. Additional litigation brought by the note holders, any additional claimed defaults under the indenture or any publicity in connection therewith could also negatively affect the market price of our Common Stock.

Future increases or decreases in the market of our Common Stock may not coincide in timing with the disclosure of news or developments by or affecting us. Accordingly, the market price of our shares of Common Stock may fluctuate dramatically, and may decline rapidly, regardless of any developments in our business. Overall, there are various factors, many of which are beyond our control, that could negatively affect the market price of our Common Stock or result in fluctuations in the price or trading volume of our Common Stock, including:

- actual or anticipated variations in our annual or quarterly results of operations, including our earnings estimates and whether we meet market expectations with regard to our earnings;
- restrictions on our ability to pay dividends or other distributions;
- publication of research reports by analysts or others about us or the motion picture exhibition industry, which may be unfavorable, inaccurate, inconsistent or not disseminated on a regular basis;
- changes in market interest rates that may cause purchasers of our shares to demand a different yield;
- changes in market valuations of similar companies;
- market reaction to any additional equity, debt or other securities that we may issue in the future, and which may or may not dilute the holdings of our existing stockholders;
- additions or departures of key personnel;
- actions by institutional or significant stockholders;
- short interest in our securities and the market response to such short interest;
- the dramatic increase or decrease in the number of individual holders of our Common Stock and their participation in social media platforms targeted at speculative investing;
- speculation in the press or investment community about our company or industry;
- strategic actions by us or our competitors, such as acquisitions or other investments;
- legislative, administrative, regulatory or other actions affecting our business or our industry, including positions taken by the Internal Revenue Service (“IRS”);
- strategic actions taken by motion picture studios, such as the shuffling of film release dates;
- investigations, proceedings, or litigation that involve or affect us;
- the occurrence of any of the other risk factors included or incorporated by reference in our Annual Report; and
- general market and economic conditions.

Filed Nov 6, 2024.
Source: SEC EDGAR, the filing index for accession 0001411579-24-000077. Last ingested by Listed: Nov 4, 2026, 17:31 ET. No prices; not investment advice.
